CN104324004A - Pioglitazone liposome combination drug and its large-scale industrial production process - Google Patents
Pioglitazone liposome combination drug and its large-scale industrial production process Download PDFInfo
- Publication number
- CN104324004A CN104324004A CN201310524614.5A CN201310524614A CN104324004A CN 104324004 A CN104324004 A CN 104324004A CN 201310524614 A CN201310524614 A CN 201310524614A CN 104324004 A CN104324004 A CN 104324004A
- Authority
- CN
- China
- Prior art keywords
- solution
- liposome
- coating
- medicine
- pioglitazone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 127
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 title claims abstract description 52
- 229960005095 pioglitazone Drugs 0.000 title claims abstract description 26
- 229940000425 combination drug Drugs 0.000 title 1
- 238000009776 industrial production Methods 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 209
- 239000007924 injection Substances 0.000 claims abstract description 64
- 238000002347 injection Methods 0.000 claims abstract description 64
- 238000002360 preparation method Methods 0.000 claims abstract description 54
- 239000002131 composite material Substances 0.000 claims abstract description 50
- 239000007921 spray Substances 0.000 claims abstract description 22
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 239000000829 suppository Substances 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims description 126
- 239000002245 particle Substances 0.000 claims description 77
- 239000007788 liquid Substances 0.000 claims description 69
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 68
- 238000000576 coating method Methods 0.000 claims description 68
- 229940079593 drug Drugs 0.000 claims description 66
- 150000003904 phospholipids Chemical class 0.000 claims description 65
- 239000011248 coating agent Substances 0.000 claims description 60
- 239000000463 material Substances 0.000 claims description 52
- 239000000203 mixture Substances 0.000 claims description 50
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 45
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 45
- 239000000811 xylitol Substances 0.000 claims description 45
- 229960002675 xylitol Drugs 0.000 claims description 45
- 235000010447 xylitol Nutrition 0.000 claims description 45
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 37
- 238000004108 freeze drying Methods 0.000 claims description 35
- 229910052757 nitrogen Inorganic materials 0.000 claims description 32
- 239000006185 dispersion Substances 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 238000009835 boiling Methods 0.000 claims description 27
- 238000000108 ultra-filtration Methods 0.000 claims description 26
- 230000001954 sterilising effect Effects 0.000 claims description 24
- 229960001051 dimercaprol Drugs 0.000 claims description 22
- 239000007787 solid Substances 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 22
- WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 20
- 239000000823 artificial membrane Substances 0.000 claims description 18
- 239000002510 pyrogen Substances 0.000 claims description 16
- 238000005374 membrane filtration Methods 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 15
- 239000012528 membrane Substances 0.000 claims description 14
- 238000005507 spraying Methods 0.000 claims description 14
- 230000001476 alcoholic effect Effects 0.000 claims description 13
- 238000011082 depyrogenation Methods 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 239000003963 antioxidant agent Substances 0.000 claims description 12
- 230000003078 antioxidant effect Effects 0.000 claims description 12
- 235000006708 antioxidants Nutrition 0.000 claims description 12
- 239000002270 dispersing agent Substances 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 12
- 238000004659 sterilization and disinfection Methods 0.000 claims description 12
- 239000004094 surface-active agent Substances 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 11
- 229910021645 metal ion Inorganic materials 0.000 claims description 10
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 8
- 235000003969 glutathione Nutrition 0.000 claims description 8
- 229960003180 glutathione Drugs 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 7
- 239000000787 lecithin Substances 0.000 claims description 7
- 229940067606 lecithin Drugs 0.000 claims description 7
- 235000010445 lecithin Nutrition 0.000 claims description 7
- 230000000844 anti-bacterial effect Effects 0.000 claims description 6
- 238000006703 hydration reaction Methods 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 6
- 150000004767 nitrides Chemical class 0.000 claims description 6
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- FKJIJBSJQSMPTI-CAOXKPNISA-M sodium;(4r)-4-[(5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-3,7,12-trioxo-1,2,4,5,6,8,9,11,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pentanoate Chemical group [Na+].C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C FKJIJBSJQSMPTI-CAOXKPNISA-M 0.000 claims description 6
- 239000008215 water for injection Substances 0.000 claims description 6
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- IGLKELDWPZFFKF-UHFFFAOYSA-N OC(C1=CC=CC=C1C(O)=O)=O.OC(C1=CC=CC=C1C(O)=O)=O.OC(C1=CC=CC=C1C(O)=O)=O.P.P Chemical compound OC(C1=CC=CC=C1C(O)=O)=O.OC(C1=CC=CC=C1C(O)=O)=O.OC(C1=CC=CC=C1C(O)=O)=O.P.P IGLKELDWPZFFKF-UHFFFAOYSA-N 0.000 claims description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 4
- 229910000831 Steel Inorganic materials 0.000 claims description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 230000003749 cleanliness Effects 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 229910001873 dinitrogen Inorganic materials 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 4
- 239000011574 phosphorus Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000012266 salt solution Substances 0.000 claims description 4
- 239000010959 steel Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 150000004291 polyenes Chemical class 0.000 claims description 3
- 230000000717 retained effect Effects 0.000 claims description 3
- 210000002706 plastid Anatomy 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 239000008363 phosphate buffer Substances 0.000 claims 2
- 230000007115 recruitment Effects 0.000 claims 1
- 229940090044 injection Drugs 0.000 description 52
- 238000012360 testing method Methods 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 238000005516 engineering process Methods 0.000 description 15
- 230000003285 pharmacodynamic effect Effects 0.000 description 13
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 10
- 229960000711 alprostadil Drugs 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000036512 infertility Effects 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 238000009826 distribution Methods 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 229930012538 Paclitaxel Natural products 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical group N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 4
- FXNFHKRTJBSTCS-UHFFFAOYSA-N baicalein Chemical compound C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 229960001592 paclitaxel Drugs 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229960000329 ribavirin Drugs 0.000 description 4
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 3
- MKBLHFILKIKSQM-UHFFFAOYSA-N 9-methyl-3-[(2-methyl-1h-imidazol-3-ium-3-yl)methyl]-2,3-dihydro-1h-carbazol-4-one;chloride Chemical compound Cl.CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 MKBLHFILKIKSQM-UHFFFAOYSA-N 0.000 description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- UFUVLHLTWXBHGZ-MGZQPHGTSA-N [(2r,3r,4s,5r,6r)-6-[(1s,2s)-2-chloro-1-[[(2s,4r)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 UFUVLHLTWXBHGZ-MGZQPHGTSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- -1 adefovir ester Chemical class 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229960002291 clindamycin phosphate Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
- 229960000770 ondansetron hydrochloride Drugs 0.000 description 3
- 159000000000 sodium salts Chemical group 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- KEJCWVGMRLCZQQ-YJBYXUATSA-N Cefuroxime axetil Chemical group N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(=O)OC(C)OC(C)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 KEJCWVGMRLCZQQ-YJBYXUATSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 229960001997 adefovir Drugs 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960004841 cefadroxil Drugs 0.000 description 2
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 2
- 229960002620 cefuroxime axetil Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 2
- 229960002963 ganciclovir Drugs 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 2
- 229960002260 meropenem Drugs 0.000 description 2
- CUXQLKLUPGTTKL-UHFFFAOYSA-M microcosmic salt Chemical compound [NH4+].[Na+].OP([O-])([O-])=O CUXQLKLUPGTTKL-UHFFFAOYSA-M 0.000 description 2
- 231100000668 minimum lethal dose Toxicity 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- BGKHCLZFGPIKKU-LDDQNKHRSA-N prostaglandin A1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1C=CC(=O)[C@@H]1CCCCCCC(O)=O BGKHCLZFGPIKKU-LDDQNKHRSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 229960004586 rosiglitazone Drugs 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- 229940083618 sodium nitroprusside Drugs 0.000 description 2
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 description 2
- JJICLMJFIKGAAU-UHFFFAOYSA-M sodium;2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)purin-6-olate Chemical compound [Na+].NC1=NC([O-])=C2N=CN(COC(CO)CO)C2=N1 JJICLMJFIKGAAU-UHFFFAOYSA-M 0.000 description 2
- 239000007962 solid dispersion Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N tanshinone IIA Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 229940093257 valacyclovir Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 2
- 229960004740 voriconazole Drugs 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 244000050510 Cunninghamia lanceolata Species 0.000 description 1
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000009338 Gastric Mucins Human genes 0.000 description 1
- 108010009066 Gastric Mucins Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PQMWYJDJHJQZDE-UHFFFAOYSA-M Methantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229960005446 cefpiramide Drugs 0.000 description 1
- RIWWMGQFMUUYIY-ALLHVENQSA-M cefpiramide sodium Chemical compound [Na+].C1=NC(C)=CC(O)=C1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C([O-])=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 RIWWMGQFMUUYIY-ALLHVENQSA-M 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- 229940065639 etoposide 100 mg Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- CAOOISJXWZMLBN-PPHPATTJSA-N htn0d03vrz Chemical compound Cl.C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 CAOOISJXWZMLBN-PPHPATTJSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- 229960004569 indapamide Drugs 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229960004169 mitoxantrone hydrochloride Drugs 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229940042880 natural phospholipid Drugs 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229940108949 paclitaxel injection Drugs 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 229960002625 pazufloxacin Drugs 0.000 description 1
- UDHGFPATQWQARM-FJXQXJEOSA-N pazufloxacin mesylate Chemical compound CS(O)(=O)=O.C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1C1(N)CC1 UDHGFPATQWQARM-FJXQXJEOSA-N 0.000 description 1
- 229950000845 politef Drugs 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000002966 stenotic effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a pioglitazone liposome composite medicament and large-scale industrial preparation thereof, which is characterized in that the molar ratio of each component raw material of the pioglitazone liposome composite medicament is disclosed; the invention is characterized in that the invention also provides a large-scale industrial preparation method of the liposome combined medicament; the pioglitazone liposome composite medicament is characterized by being prepared into a freeze-dried injection, an oral preparation, a spray or a suppository of the pioglitazone liposome composite medicament according to the pharmaceutically allowable dose.
Description
The application is for enjoying domestic priority application.Earlier application state is China, and the number of patent application of earlier application is 201010240184.0, and the applying date is on 07 29th, 2010, and name is called " dissolving ultrafiltration-spraying dry-molecule dispersion coating-hydration palletizing-freeze drying method for preparing liposome combination medicine ", the application is again divisional application, earlier application state is China, the number of patent application of earlier application is 201110212139.9, the applying date is on 07 28th, 2011, name is called " liposome composite medicine such as Alprostadil and large industrialized producing technology and purposes " thereof, the number of patent application that this patent enjoys the earlier application of domestic priority is 201010240184.0, the applying date is on 07 29th, 2010, name is called " dissolving ultrafiltration-spraying dry-molecule dispersion coating-hydration palletizing-freeze drying method for preparing liposome combination medicine ", on 07 12nd, 2013, dispatch sequence number is in " the first time notification of examiner's opinion " of 2013070900958420, auditor proposes divisional application.
Technical field
The present invention relates to a kind of large suitability for industrialized production liposome composite medicine preparation method, it is characterized in that, subject matter is with dissolving ultrafiltration-spray drying-molecule dispersion coating-hydration palletizing-freeze-drying, both can suitability for industrialized production liposomal body composition injection greatly with unified formula, technique, equipment, again can suitability for industrialized production liposomal body composition oral preparation greatly.
Background technology
China's pharmaceutical technology, crude drug technology of preparing and international most advanced level gap are only within 5 years, and what have meets or exceeds international most advanced level, and preparation technique will fall behind international most advanced level 20 years.Now a large amount of is produce secondary ordinary preparation, and three generations's slow release, controlled release agent, especially four generation the targeting preparation such as liposome be only in the laboratory research stage at present.Reason has:
1, liposome medicament technology injection and oral formulations formula, technique, equipment disunity are prepared in existing production, scientific research, have both wasted resource, the energy, and investment is large, of low quality again, contaminated environment.
2, the method for liposome medicament suitability for industrialized production may be made in prior art to have: high pressure homogenization, supercritical ultrasonics technology, organic solvent seasoning, spray drying method, fluidized bed coating, single phase soln freeze-drying.High pressure homogenization and supercritical ultrasonics technology size tunable, but high energy is broken, has destruction to crude drug; Rear four kinds of methods to particle diameter uncontrollable and particle size distribution do not concentrate, organic solvent residual, the quality problems such as have leakage, precipitation, cohesion, phospholipid corrupt;
3, existing method for preparing lipidosome makes the envelop rate of lipidosome drug carrier not reach 100%, and each batch of fluctuation, change are large; Slip is large, loses liposome medicament meaning;
4, production process is turned from side to side many, and during energy charge, equipment investment is large, prescription, technique shakiness by, immature, cause that the quality of the pharmaceutical preparations is uncontrollable, unstable, poor reproducibility;
5, sterilizing, depyrogenation method are improper, and omnidistance aseptic, apyrogeneity operation is difficult to ensure, lacks height aseptic concept to liposome medicament, cause liposome medicament corrupt under antibacterial corrodes, envelop rate falls progressively, and slip increases progressively, effect duration is extremely short, almost loses medical value;
6, injection indissolubility population and particle diameter exceed standard;
7, crude drug, phospholipid and adjuvant, solvent selection do not have national drug quality standard mostly, and have patent also do not criticize New Drug Certificate and produce certification, registration difficulty is very large, chronic;
8, depart from Chinese truth, obtain liposome new drug production certification from developing to, spend nearly 10 years, cost more than 2,000 ten thousand yuan, better drug discovery patent, exhausted most enterprise dare not be invested and developed.Visible, medical reform and national system for basic pharmaceutical period is carried out in country, the large product of sales volume is selected to rise to the Liposomal formulation of forth generation from entering the secondary preparation of national essential drugs, carry out preparation technique innovation, eliminate its side effect and untoward reaction, such medicine sales volume is large, and investment recovery time is short.Reach safety, effective, high-quality, this basic principle economic.
Summary of the invention
The present invention seeks to the defect overcoming above-mentioned prior art.Theme of the present invention is: with dissolving ultrafiltration-spray drying-molecule dispersion coating-hydration palletizing-freeze-drying, both can suitability for industrialized production liposomal body composition injection greatly with unified formula, technique, equipment, again can suitability for industrialized production liposomal body composition oral preparation greatly.Specification formula and the normalized process for preparing of dissolving ultrafiltration-spray drying-molecule dispersion coating-hydration palletizing-lyophilization suitability for industrialized production liposome composite medicine are provided.Formed secondary pharmaceutical preparation innovation rise to four generation targeting preparation.
The present invention is achieved by the following technical solutions:
The each component feed molar number of the specification of suitability for industrialized production liposome composite medicine of the present invention is than as follows:
Described crude drug is strong fat-soluble strong or water solublity powerful feature, and formula dosage is 1/1 to five/3rd of the oral or injection preparation minimum gauge amount of formulation of existing secondary correspondence.Preferred: the compositions of Alprostadil and indapamide mole ratio 1:30, or the compositions of CEFUROXIME AXETIL and Alprostadil mole ratio 2500:1, or fluconazol, or voriconazole, or sorbide nitrate, or the compositions of ribavirin and cefadroxil mole ratio 1:1, or the compositions of paclitaxel and Alprostadil molal quantity 333:1, or clindamycin phosphate, or ganciclovir, or noroxylin, or tanshinone IIA, or prostaglandin A
1, or meropenem, or pioglitazone, or rosiglitazone, or simvastatin, or cytosine arabinoside, or hydroxy camptothecin, or sodium nitroprusside, or valaciclovir, or doxorubicin, or etoposide, or adefovir ester, or ribavirin and Alprostadil weight ratio 1000:1 compositions, or ligustrazine microcosmic salt or Pazufloxacin Mesilate, or cefpiramide sodium, or mitoxantrone, or Ondansetron Hydrochloride.
The mean molecule quantity of described lecithin materials all defines and calculates with 800D, and lecithin materials is the compositions of hydrogenated soy phosphatidyl choline and polyene phosphatidylcholine, and mole ratio is the compositions of 1-5:0.5.
The antioxidant of described phospholipid is reduced glutathion.
Described immobilized artificial membrane molecular state diluent, or claim phospholipid dispersions, or claim immobilized artificial membrane dispersant, being again antioxidant, is dimercaprol.
Described liposome medicine carrying body dispersant, being again excipient, is xylitol.
Described surfactant is sodium dehydrocholate.
The each component raw material of liposome composite medicine all should have national standard, and is all the national standard of pharmaceutical injection agent level.Both meet national GMP specification, meet again the regulation of country's " drug registration management method ", in order to industrialization development.
The present invention also provides the normalized process for preparing of described liposome composite medicine:
1, in dissolving tank, xylitol dosage is dissolved in injection phosphorus phthalate buffer the weight percent solution of 10% of xylitol, by this solution 121 DEG C of steam sterilizations 20 minutes, when solution temperature is 20-25 DEG C, with the ultrafiltration post ultrafiltration of the ultrafilter membrane of molecular cut off 1000D, except the pyrogen in solution and pyrogen molecule fragment, get the solution that ultrafiltration obtains; Again at room temperature, the solution that decile ultrafiltration obtains, be divided into A, B solution, A, B solution are used respectively the analytical pure sodium hydroxide solution adjust pH 8.5 of 5%-8%, by A, B solution respectively through the membrane filtration mistake in less than 0.05 μm aperture, remove the precipitate of insoluble particle, high volence metal ion, metal ion, then be 5.0-8.0 with the analytically pure hydrochloric acid solution adjust pH of 8% respectively by A, B solution.If the crude drug that water solublity is strong dissolves completely with appropriate water for injection, with the membrane ultrafiltration of molecular cut off 1000D, depyrogenation, gained ultrafiltration solution is merged in B solution and stirs, again through 0.05 μm of following membrane filtration mistake in aperture, bacterium, insoluble particle in removing raw material medicine solution.Raw material medicinal liquid requires that inspection pyrogen and qualified could the permission of insoluble particle add in B solution.If fat-soluble crude drug dissolves then by the 3rd step process below.
2, by solution A in the spray dryer preparing pharmaceutical injection agent level, by spraying dry well-established law, solution A (is come by compressor with cleanliness factor 100 grades of compressed airs by the spraying nozzle at equipment top, room temperature) mixing ejection, the temperature entered with device bottom 150 DEG C of-190 DEG C of 100 grades of pure airs (are attracted by air-introduced machine, high temperature) gas-liquid counter current mixing, be spray dried to 120-150 order left and right porous granule dry powder.Dry complete, it is for subsequent use that dried material leaves this device bottom in.
3, stirring and dissolving in fat-soluble crude drug, phospholipid, phospholipid dispersions to ethanol is added respectively complete, make proportion 1.0 to 1.2 solution, through the membrane ultrafiltration of molecular cut off 1000D, then through less than 0.05 μm aperture membrane filtration mistake, except pyrogen removal, antibacterial, insoluble particle.
The composition dries granule of the solution A 4, the 2nd step prepared, is put in boiling seed-coating machine, by boiling coating and the operation of airpillow-dry well-established law, first divides three parts by phospholipid alcoholic solution equal-volume prepared by the 3rd step.Introducing is changed into anhydrous in device bottom, aseptic, without oil, without the room temperature purity nitrogen air-flow of the particle of more than 0.001 μm particle diameter, at 40 DEG C of-65 DEG C of temperature, coating under boiling fluidized state is carried out to the dry thing particle of the xylose that the 2nd step is obtained: first by (1/3rd volumes) phospholipid alcoholic solution of first part, by being that 100 grades of pure nitrogen gas mix with compressed clean rank in the coating nozzle in the middle part of transport pump to equipment, the thick that in machine, boiling is highly flowed for 400mm-450mm material (xylitol) is sprayed onto in spray form, at boiling material particle surface coating, material simultaneous altitude under boiling is mixed and dispersion equably, and make solvent volatilize as quick as thought, form porosu solid coating thin layer, the alcoholic solution feed liquid coating of first three/monophosphatide completes, airpillow-dry 15 minutes, the B solution first step prepared again is decile three parts also, by 1/3rd solution of the volume of first part of B solution anhydrous, aseptic, without oil, in 100 grades of purity nitrogen air-flows without the particle of more than 0.001 μm particle diameter, by aforesaid operations coating, after coating, airpillow-dry 20 minutes, carry out first time coating-drying process like this, repeat above-mentioned coating-drying process, the solution carrying out 1/3rd volumes of second part of second, third time two kinds of solution, the 3rd part respectively carries out the alternately coating-drying process of phospholipid liquid and B solution by aforesaid operations.Outermost layer coatings is the dry nitride layer of xylitol micropore, or water-soluble crude drug, xylitol the dry nitride layer of micropore of compositions, after third time coating, residual moisture content≤1.0% in the coating dried material obtained, residual dimercaprol≤0.2%.Note, if water miscible crude drug, be then crude drug and xylitol in B solution to dried particles three coatings of solution A, not containing crude drug in its alcoholic solution.
5, in material-compound tank, add the isopyknic water for injection of injection phosphorus acid salt solution with the first step, in tank, inflated with nitrogen and tank external pressure maintain an equal level, and under 100 revs/min of mixing speeds, are heated to 60 ± 5 DEG C; Tune speed of agitator is 500-700 rev/min, in tank under inflated with nitrogen, in 30 minutes to 60 minutes, dry for coating obtained for the 4th step thing is joined in material-compound tank; After adding the dry thing of coating, in tank under inflated with nitrogen environment, keep temperature 60 ± 5 DEG C, and keep 60-120 minute under stirring at 100 revs/min; Under stirring at 100 revs/min again, tank inner liquid medicine is cooled to 30-40 DEG C; Under stirring at 100 revs/min again, add antioxidant glutathion and sodium dehydrocholate respectively and dissolve completely, and adjust medicinal liquid pH value 5.0-8.0.
6, hold temperature within the scope of 30 ± 5 DEG C at guarantor's medicinal liquid, under 0.1-0.2Mpa nitrogen pressure, cross the obtained medicinal liquid of the 5th step by 0.15 μm of membrane filtration, get the medicinal liquid of filtration, obtain the liposome medicinal liquid that particle diameter is less than 150nm.Allow the dosage subpackage liposome medicinal liquid of this medicine in cillin bottle by pharmaceutics, and partly jump a queue, well-established law lyophilization in the freeze drying box of lyophilization unit.To medicine solid residue moisture for being less than 2%, dimercaprol residual quantity is for being less than 0.2%.Vacuum tamponade, rolls lid, and be up to the standards laggard storehouse.Make the lyophilized injection of the nanometer particle size of liposome medicine carrying body.This lyophilized injection also can be made into aseptic spray.
7, under 100 grades of sterilization grade, on the filter membrane that 6th step is filtered the Lipid pharmaceutical granule being greater than 150nm that retains wash 10% by the 1st step operation sterilizing, freshly prepd 10% xylitol solution of depyrogenation, measure the content of total phospholipids raw material in medicinal liquid, and with the qualified freshly prepd 10% xylitol solution adjustment medicine liquid volume of sterilizing depyrogenation, reach and to control in medicinal liquid total phospholipids content at 40-80mg/ml; This medicinal liquid is joined in another batching filling, and under rushing nitrogen, 100 revs/min of mixing speeds, are heated to 50 ± 5 DEG C in 30-60 minute, keep this temperature range to stir 60-120 minute; Under keeping rushing nitrogen again, 100 revs/min of rotating speeds, cooling medicinal liquid is to 20-25 DEG C, and medicinal liquid is dispensed in the rustless steel pallet of 316L, and be put in the freeze drying box of another lyophilizing unit, well-established law lyophilization, to medical solid, moisture is less than 2%.Dimercaprol residual quantity is for being less than 0.2%.Obtain liposome medicament solid, liposome medicament solid under 100 grades of sterilization grade, be crushed to 80-100 orders, the dosage allowed by pharmaceutics, well-established law makes the aseptic enteric oral preparation of this medicine, asepticly fastens agent.
8, all operations all should carry out in strict accordance with injection sterility requirements in national GMP specification.Oral formulations also must be undertaken by injection sterility requirements.
Liposome medicament of the present invention, aseptic freeze-dried injection in use, when dissolving by transfusion aquation in cillin bottle, phospholipid dispersions disperses liposome medicine carrying body rapidly, and under xylitol liquid surface tension and Action of Surfactant, form the liposome medicine carrying uniform particle dispersion of particle diameter 50nm-150nm scope single chamber nanometer particle size; Oral formulations forms 150-1000nm particle at enteral.Envelop rate is all 100%.Liposome medicine carrying body is dispersed in 6 hours internal leakage rates less than 5% in transfusion, does not precipitate, does not condense, not stratified, is uniformly dispersed.After drug oral of the present invention, in gastrointestinal fluid, dispersion forms single chamber and multicell Coliposomes medicine, improves the therapeutic index of medicine.
Advantage of the present invention has:
1, both can suitability for industrialized production liposomal body composition injection greatly with unified formula, technique, equipment, again can suitability for industrialized production liposomal body composition oral preparation greatly.
2, with the develop of secondary preparation and the innovative combination of secondary preparation process prepare four generation targeting preparation, make mysterious liposome medicament from laboratory implementation industrialization steady production.Specification formula, the normalized process for preparing of liposome composite medicine are opened up, and be injection, oral formulations, other route of administration preparation have unified core formulation and preparation method, produce in cheap apparatus, greatly save Factory Building, equipment, manpower, time, the energy, also can realize zero emission.
3, the present invention focuses on theory ground-breaking and brings innovative technology to break through: with safety, effectively, high-quality, this basic principle economic, to invention medicine from selecting materials, to preparation process, be all high request ground to using final liposome medicament to be distributed in transfusion omnidistance aseptic, pyrogen, particle diameter, particle size distribution, envelop rate, slip, Decayed rate, the rate of settling to medicine, cohesion rate, effect duration etc., perfect meet this basic principle, pharmaceutical industry of the present invention is melted send out listing risk little.
4, the medicine core technology in the present invention has: lecithin materials molal quantity input amount breaks through prior art consumption, it is 5 times of prior art consumption, it is 10 times of crude drug, and crude drug is the medicine selecting fat-soluble or water solublity to be better than dispersant xylitol, phospholipid is greater than the envelop rate to xylitol widely to the envelop rate of medicine, and envelop rate reaches 100%; Lecithin materials consumption is large simultaneously, and there is a large amount of blank liposome, blank liposome is by macrophage phagocytic in vivo, and drug-loaded liposome is engulfed less, and curative effect is higher; Surfactant is dissolved in liposomal phospholipids rete, liposome bilayers is risen " shutoff ", reinforcement effect, this is because Liposomal surfactant agent is sodium salt, when pH value such as dissolving normal saline and glucose etc. is less than in 6 transfusions, its sodium salt of part becomes water-fast acid molecule, and enter in phospholipid bilayer, cholesterol is replaced also to play " shutoff ", reinforce liposome particles effect, make slip very little, surfactant also has the precipitation of lipotropism plastid in transfusion, cohesion, also has and strengthens liposomal dispersion uniformly liposome transfusion effect; Owing to adding immobilized artificial membrane dispersant dimercaprol, when coating is dry, immobilized artificial membrane is made to be that the micropore solid dispersion of molecular state replaces that high pressure impingement is broken, the broken immobilized artificial membrane particle of ultrasound waves, thousands of times less of the lecithin materials particle of high pressure impingement fragmentation, when coating, xylitol replaces the dimercaprol position of volatilization, composition phospholipid and xylitol molecules state microporous solids dispersion, make xylitol become the dispersant of liposome; This research finds, xylitol also has protection liposome medicine carrying body when lyophilization not by the protective effect that little ice slag destroys with mannitol sample, but mannitol has stimulation when intravenous drip to blood vessel; Dimercaprol is antioxidation when coating, and protection glutathion, phospholipid, crude drug are not oxidized, make glutathion play antioxidation and anti-peroxidation group use in vivo, and the liver protecting is not by drugs damage; This research of phospholipid material finds, this saturated phospholipid of hydrogenated soy phosphatidyl choline and polyene phosphatidylcholine compositions make that liposome is stable, slip is low, phospholipid to human body without antigen and harmless to liver; The lyophilization again of liposome dispersed system made by lipidosome freeze-dried injection of the present invention, when aquation again, keep liposome physics and chemical property constant.
5, because the particle diameter of above-mentioned effect medicine of the present invention in transfusion, particle size distribution are constant, envelop rate 100%, slip≤5%, Decayed rate are 0%, sedimentation rate is 0%, cohesion rate is 0%, eliminate the accumulating of liposome medicament refrigerator, content and envelop rate falls progressively, slip is risen progressively, effect duration is shorter than four big world property difficult problems of crude drug.Become satisfactorily excellent can be practical four generation preparation.
6, the liposome medicament prepared of the present invention, in immobilized artificial membrane, phospholipid becomes solid solution to be scattered in immobilized artificial membrane with molecularity to inhale and release in agent and surfactant, and thousands of times less of supercritical ultrasonics technology, the broken phospholipid particles of high-pressure uniform matter; When coating-drying, the volatilization of solvent and dimercaprol makes phospholipid rete form countless small aperture layer, it is much bigger that this forms network structure specific surface area than freeze-drying, because hydrone distillation volatilization distance thousands of times longer than coatings distance in solid, makes network structure dissolve condensation in freeze-drying process; Again because phospholipid rete and xylose alcohol layer are immobilized artificial membrane dispersant layers, rapid, the high degree of dispersion phospholipid when aquation.These three kinds of advantages, the liposome particles particle diameter formed than prior art is more stable, more form nanometer size range to favorable reproducibility, and particle diameter is normal distribution.
7, composition of medicine of the present invention due to choosing phospholipid be natural phospholipid, human body and microbial cell film component, better targeting drug release function is had to pathogenic bacteria, virocyte, tumor cell and vascular wall damage place, therapeutic index is high, so crude drug consumption is only 1/1 to five/3rd of secondary medicine, add the encapsulating of phospholipid, the untoward reaction of crude drug almost without.The consumption of crude drug reduces, and strengthens phospholipid consumption, guarantees that envelop rate reaches 100%, and have " shutoff " to reinforce the surfactant of liposome effect, so slip is zero.
8, the immobilized artificial membrane dispersant of composition of medicine of the present invention is again the proppant of immobilized artificial membrane coating.Be again the material with liposome particles size during surfactant co-controlling proliposome aquation, they are caused by the surface tension effects forming certain limit in aqueous.Xylitol can supply energy to diabetes, hepatopath, is desirable immobilized artificial membrane dispersant and excipient.
9, the immobilized artificial membrane diluent of composition of medicine of the present invention; by being not only dissolved in ethanol but also water-soluble; volatilize when spraying dry; form the micropore phospholipid rete that immobilized artificial membrane becomes molecular state solid dispersion system; when aquation in immobilized artificial membrane phospholipid be with molecular state degree of crushing and and surface dispersant phospholipid is distributed in water; form uniform nanoparticle liposome medicine carrying body, dimercaprol is wherein again the antioxidant of excellent liposome, protects phospholipid and medicine when coating.
10, the Action of Surfactant first of composition of medicine of the present invention when phospholipid aquation, phospholipid is distributed in water, second in the transfusion entering pH value 4.0-6.0, it is molecular structure organic acid by sodium salt acidify again, enter again in the two point lipid layer of liposome, play liposome " shutoff " reinforcement effect, the 3rd plays Action of Surfactant at surface of liposome.
11, the present invention can make liposome medicament effect duration reach 1 year, adopts four effective measures: one is added antioxidant, and protection immobilized artificial membrane and crude drug are not oxidized; Two is in phospholipid dispersions coatings outside immobilized artificial membrane coatings, and bag protects phospholipid rete; Three are oral formulations is also by injection selection, sterilizing and sterile working, and eliminate antibacterial and decompose the corruption of phospholipid, this is the place of all existing lipidosome oral preparations and even injection technology significant error; Four be liposomal dispersion in transfusion in, there is metal ion in the dimercaprol complexation transfusion of 0.2%, make the metal ion brought in transfusion can not destroy phospholipid and liposome medicine carrying body, at vitamin C-glutathion-dimercaprol combination antioxidant, do not leak under Liposomal surfactant agent, dispersant combined effect, do not precipitate, not stratified, do not condense, be not oxidized, not corrupt, thus make liposome carry real mistake of about body to have actual use value difficulty.Liposome medicine carrying body is dispersed in transfusion, and due under the effect of the defect of liposome own and transfusion, making liposome composite medicine produce qualitative change, is also the significant error part that the present invention makes up prior art.
12, liposome medicament of the present invention is in preparation process, phospholipid liquid and the phospholipid dispersions liquid membrane filtration all below 0.05 μm of aperture is crossed (usual injection preparation is all cross through 0.22 μm of membrane filtration), make indissolubility particle diameter be down to 1/4th of permissible value, after making liposome aquation, particle diameter 50nm to 150nm particle is liposome particles entirely.Can the particle diameter of Accurate Measurement liposome medicine carrying body and particle size distribution.This is also the place that the present invention makes up prior art significant error.
Detailed description of the invention:
Embodiment 1
Crude drug is that each material component mole ratio of fat-soluble strong liposome composite medicine specification is as follows:
The specification preparation process of the present embodiment and method:
1, in dissolving tank, xylitol dosage is dissolved in injection phosphorus phthalate buffer the weight percent solution of 10% of xylitol, by this solution 121 DEG C of steam sterilizations 20 minutes, when solution temperature is 20-25 DEG C, with the ultrafiltration post ultrafiltration of the ultrafilter membrane of molecular cut off 1000D except the pyrogen in solution and pyrogen molecule fragment, get the solution that ultrafiltration obtains; Again at room temperature, the solution that decile ultrafiltration obtains is A, B solution, A, B solution are used respectively the analytical pure sodium hydroxide solution adjust pH 8.5 of 5%-8%, by A, B solution respectively through the membrane filtration mistake in less than 0.05 μm aperture, remove the precipitate of insoluble particle, high volence metal ion, metal ion, then be 5.0-8.0 with the analytically pure hydrochloric acid solution adjust pH of 8% respectively by A, B solution.Material solution require inspection pyrogen and insoluble particle qualified.
2, by solution A in pharmaceutical injection agent level spray-type fluidized bed dryer, by spraying dry well-established law, solution A (is come by compressor with cleanliness factor 100 grades of compressed airs by the spraying nozzle at equipment top, room temperature) mixing ejection, the temperature entered with device bottom 150 DEG C of-190 DEG C of 100 grades of pure airs (are attracted by air-introduced machine, high temperature) gas-liquid counter current mixing, be spray dried to 120-150 order left and right porous granule dry powder.Dry complete, it is for subsequent use that dried material leaves this device bottom in.
3, stirring and dissolving in fat-soluble crude drug, phospholipid, phospholipid dispersions to ethanol is added respectively complete, if crude drug dissolves undesirable, a small amount of dichloromethane can be added in ethanol, to crude drug dissolubility ideal, do not add as far as possible and add methylene chloride less as far as possible, make proportion 1.0 to 1.2 solution, through the politef material membrane ultrafiltration of molecular cut off 1000D, filter, except pyrogen removal, antibacterial, insoluble particle through less than 0.05 μm aperture titanium film again.
The composition dries granule of the solution A 4, the 2nd step prepared, is put in spraying boiling coating-boiling drier, by boiling coating, the operation of airpillow-dry well-established law, first divides three parts by phospholipid alcoholic solution equal-volume prepared by the 3rd step.Introducing is changed into anhydrous in device bottom, aseptic, without oil, without the room temperature purity nitrogen air-flow of the particle of more than 0.001 μm particle diameter, at 40 DEG C of-65 DEG C of temperature, coating under boiling fluidized state is carried out to the dry thing particle of the xylose that the 2nd step is obtained: first by (1/3rd volumes) phospholipid alcoholic solution of first part, by being that 100 grades of pure nitrogen gas mix with compressed clean rank in the coating nozzle in the middle part of transport pump to equipment, spray form is sprayed onto the thick that in machine, boiling is highly flowed for 400mm-450mm material (fructose and mannitol compositions), at boiling material particle surface coating, material simultaneous altitude under boiling is mixed and dispersion equably, and make solvent volatilize as quick as thought, form porosu solid coating thin layer, the alcoholic solution feed liquid coating of first three/monophosphatide completes, airpillow-dry 15 minutes, the B solution first step prepared again is decile three parts also, by 1/3rd solution of the volume of first part of B solution anhydrous, aseptic, without oil, in 100 grades of purity nitrogen air-flows without the particle of more than 0.001 μm particle diameter, by aforesaid operations coating, after coating, airpillow-dry 20 minutes, carry out first time coating-drying process like this, repeat above-mentioned coating-drying process, the solution carrying out 1/3rd volumes of second part of second, third time two kinds of solution, the 3rd part respectively carries out the alternately coating-drying process of phospholipid liquid and B solution by aforesaid operations.Outermost layer coatings is the dry nitride layer of xylitol micropore, or water-soluble crude drug, xylitol the dry nitride layer of micropore of compositions, after third time coating, residual moisture content≤1.0% in the coating dried material obtained, residual dichloromethane and ethanol are 0%, residual dimercaprol≤0.2%.
5, in material-compound tank, the isopyknic water for injection of injection phosphorus acid salt solution with the first step is added, in tank, inflated with nitrogen and tank external pressure maintain an equal level, under 100 revs/min of mixing speeds, be heated to 60 ± 5 DEG C, tune speed of agitator is 500-700 rev/min, in tank under inflated with nitrogen, in 30 minutes-60 minutes, dry for coating obtained for the 4th step thing is joined in material-compound tank, after adding the dry thing of coating, in tank under inflated with nitrogen environment, keep temperature 60 ± 5 DEG C, and keep 60-120 minute under stirring at 100 revs/min.Under stirring at 100 revs/min again, tank inner liquid medicine is cooled to 30-40 DEG C.Under stirring at 100 revs/min again, add antioxidant glutathion and sodium dehydrocholate respectively and dissolve completely, and adjust medicinal liquid pH value 5.0-8.0.
6, hold temperature within the scope of 30 ± 5 DEG C at guarantor's medicinal liquid, under 0.1-0.2Mpa nitrogen pressure, cross the obtained medicinal liquid of the 5th step by 0.15 μm of membrane filtration, get the medicinal liquid of filtration, obtain the liposome medicinal liquid that particle diameter is less than 150nm.Allow the dosage subpackage liposome medicinal liquid of this medicine in cillin bottle by pharmaceutics, and partly jump a queue, well-established law lyophilization in the freeze drying box of lyophilization unit.To medicine solid residue moisture for being less than 2%, dimercaprol residual quantity is less than 0.2%, and it is all 0% that ethanol and dichloromethane remain.Vacuum tamponade, rolls lid, and be up to the standards laggard storehouse.Make lyophilized injection.This lyophilized injection can be made into aseptic spray.
7, under 100 grades of sterilization grade, the Lipid pharmaceutical granule being greater than 150nm that the filter membrane 6th step filtered retained is washed in the xylitol solution qualified by the 1st step operation sterilizing depyrogenation of 10%, measure the content of total phospholipids raw material in medicinal liquid, and with the qualified 10% xylitol solution adjustment medicine liquid volume of sterilizing depyrogenation, reach and to control in medicinal liquid total phospholipids content at 40-80mg/ml.Medicinal liquid is joined in another batching filling, under rushing nitrogen, 100 revs/min of mixing speeds, 50 are heated in 30-60 minute ± DEG C, this temperature range is kept to stir 60-120 minute, under keeping rushing nitrogen again, 100 revs/min of rotating speeds, cooling medicinal liquid, to 20-25 DEG C, is dispensed into Pharmaceutical in the rustless steel pallet of 316L, is put in the freeze drying box of another lyophilizing unit, well-established law lyophilization, to medical solid, moisture entrapment amount is less than 2%, and dimercaprol residual quantity is little by 0.2%, and it is 0% that ethanol and dichloromethane remain.Obtain liposome medicament solid, liposome medicament solid under 100 grades of sterilization grade: be crushed to 80-100 orders, the dosage allowed by pharmaceutics, well-established law makes the aseptic enteric oral preparation of this medicine, asepticly fastens agent.
8, all operations all should carry out in strict accordance with injection sterility requirements in national GMP specification.Oral formulations also must be undertaken by injection sterility requirements.
Embodiment 2
Crude drug is that each material component mole ratio of fat-soluble strong liposome composite medicine specification is as follows:
The specification preparation process of the present embodiment and method are with embodiment 1.
Embodiment 3
Crude drug is that each material component mole ratio of fat-soluble strong liposome composite medicine specification is as follows:
The specification preparation process of the present embodiment and method are with embodiment 1.
Embodiment 4
Crude drug is that each material component mole ratio of fat-soluble strong liposome composite medicine specification is as follows:
The specification preparation process of the present embodiment and method are with embodiment 1.
Embodiment 5
Crude drug is that each material component mole ratio of fat-soluble strong liposome composite medicine specification is as follows:
The specification preparation process of the present embodiment and method are with embodiment 1.
Embodiment 6
Crude drug is that each material component mole ratio of fat-soluble strong liposome composite medicine specification is as follows:
The specification preparation process of the present embodiment and method are with embodiment 1.
Embodiment 7
Crude drug is that each material component mole ratio of fat-soluble strong liposome composite medicine specification is as follows:
The specification preparation process of the present embodiment and method are with embodiment 1.
Embodiment 8
Crude drug is that each material component mole ratio of fat-soluble strong liposome composite medicine specification is as follows:
The specification preparation process of the present embodiment and method are with embodiment 1.
Embodiment 9
Crude drug is that each material component mole ratio of fat-soluble strong liposome composite medicine specification is as follows:
The specification preparation process of the present embodiment and method are with embodiment 1.
Embodiment 10
Crude drug is that each material component mole ratio of fat-soluble strong liposome composite medicine specification is as follows:
The specification preparation process of the present embodiment and method are with embodiment 1.
Fat-soluble crude drug described in above embodiment, or the compositions of CEFUROXIME AXETIL and Alprostadil mole ratio 2500:1, or fluconazol, or voriconazole, or sorbide nitrate, or the compositions of ribavirin and cefadroxil mole ratio 1:1, or the compositions of paclitaxel China fir alcohol and Alprostadil molal quantity 333:1, or clindamycin phosphate, or hydrogen artemisic succinate, or noroxylin, or Alprostadil, or tanshinone IIA, or prostaglandin A
1, or dihomo-gamma-linolenic acid or hydroxy camptothecin, or simvastatin, or pioglitazone, or rosiglitazone, or adefovir ester, or ribavirin and Alprostadil weight ratio 1000:1 compositions, or mitoxantrone.
Embodiment 11
Crude drug is that each material component mole ratio of the liposome composite medicine specification that water solublity is strong is as follows:
The specification preparation process of the present embodiment and method:
1, in dissolving tank, xylitol dosage is dissolved in injection phosphorus phthalate buffer the weight percent solution of 10% of xylitol, by this solution 121 DEG C of steam sterilizations 20 minutes, when solution temperature is 20-25 DEG C, with the ultrafiltration post ultrafiltration of the ultrafilter membrane of molecular cut off 1000D except the pyrogen in solution and pyrogen molecule fragment, get the solution that ultrafiltration obtains; Again at room temperature, the solution that decile ultrafiltration obtains is A, B solution, A, B solution are used respectively the analytical pure sodium hydroxide solution adjust pH 8.5 of 5%-8%, by A, B solution respectively through the membrane filtration mistake in less than 0.05 μm aperture, remove the precipitate of insoluble particle, high volence metal ion, metal ion, then be 5.0-8.0 with the analytically pure hydrochloric acid solution adjust pH of 8% respectively by A, B solution.Dissolved completely by the appropriate water for injection of crude drug strong for water solublity, with the membrane ultrafiltration of molecular cut off 1000D, depyrogenation, is merged in B solution and stirs, then through 0.05 μm of following membrane filtration mistake in aperture, except bacterium in crude drug, except insoluble particle.Raw material medicinal liquid requires that inspection pyrogen and qualified could the permission of insoluble particle add in B solution.
2, solution A is being prepared in pharmaceutical injection agent level spray dryer, by spraying dry well-established law, solution A (is come by compressor with cleanliness factor 100 grades of compressed airs by the spraying nozzle at equipment top, room temperature) mixing ejection, the temperature entered with device bottom 150 DEG C of-190 DEG C of 100 grades of pure airs (are attracted by air-introduced machine, high temperature) gas-liquid counter current mixing, be spray dried to 120-150 order left and right porous granule dry powder.Dry complete, it is for subsequent use that dried material leaves this device bottom in.
3, to add in phospholipid, phospholipid dispersions to ethanol stirring and dissolving respectively complete, make proportion 1.0 to 1.2 solution, through the membrane ultrafiltration of molecular cut off 1000D, then through less than 0.05 μm aperture membrane filtration mistake, except pyrogen removal, antibacterial, insoluble particle.
The composition dries granule of the solution A 4, the 2nd step prepared, is put in spraying boiling coating-boiling drier, by boiling coating, the operation of airpillow-dry well-established law, first divides three parts by phospholipid alcoholic solution equal-volume prepared by the 3rd step.Introducing is changed into anhydrous in device bottom, aseptic, without oil, without the room temperature purity nitrogen air-flow of the particle of more than 0.001 μm particle diameter, at 40 DEG C of-65 DEG C of temperature, coating under boiling fluidized state is carried out to the dry thing particle of the xylitol that the 2nd step is obtained: first by (1/3rd volumes) phospholipid alcoholic solution of first part, by being that 100 grades of pure nitrogen gas mix with compressed clean rank in the coating nozzle in the middle part of transport pump to equipment, spray form is sprayed onto the thick that in machine, boiling is highly flowed for 400mm-450mm material (fructose and mannitol compositions), at boiling material particle surface coating, material simultaneous altitude under boiling is mixed and dispersion equably, and make solvent volatilize as quick as thought, form porosu solid coating thin layer, the alcoholic solution feed liquid coating of first three/monophosphatide completes, airpillow-dry 15 minutes, the B solution first step prepared again is decile three parts also, by 1/3rd solution of the volume of first part of B solution anhydrous, aseptic, without oil, in 100 grades of purity nitrogen air-flows without the particle of more than 0.001 μm particle diameter, by aforesaid operations coating, after coating, airpillow-dry 20 minutes, carry out first time coating-drying process like this, repeat above-mentioned coating-drying process, the solution carrying out 1/3rd volumes of second part of second, third time two kinds of solution, the 3rd part respectively carries out the alternately coating-drying process of phospholipid liquid and B solution by aforesaid operations.Outermost layer coatings is the dry nitride layer of micropore of compositions of water-soluble crude drug, xylitol, and after third time coating, residual moisture content≤1.0% in the coating dried material obtained, residual dimercaprol≤0.2%, Residual ethanol is 0%.
5, in material-compound tank, the isopyknic water for injection of injection phosphorus acid salt solution with the first step is added, in tank, inflated with nitrogen and tank external pressure maintain an equal level, under 100 revs/min of mixing speeds, be heated to 60 ± 5 DEG C, tune speed of agitator is 500-700 rev/min, in tank under inflated with nitrogen, in 30 minutes-60 minutes, dry for coating obtained for the 4th step thing is joined in material-compound tank, after adding the dry thing of coating, in tank under inflated with nitrogen environment, keep temperature 60 ± 5 DEG C, and keep 60-120 minute under stirring at 100 revs/min.Under stirring at 100 revs/min again, tank inner liquid medicine is cooled to 30-40 DEG C.Under stirring at 100 revs/min again, add antioxidant reduced glutathion and sodium dehydrocholate respectively and dissolve completely, and adjust medicinal liquid pH value 5.0-8.0.
6, keeping fluid temperature within the scope of 30 ± 5 DEG C, under 0.1-0.2Mpa nitrogen pressure, crossing the obtained medicinal liquid of the 5th step by 0.15 μm of membrane filtration, getting the medicinal liquid of filtration, obtain the liposome medicinal liquid that particle diameter is less than 150nm.Allow the dosage subpackage liposome medicinal liquid of this medicine in cillin bottle by pharmaceutics, and partly jump a queue, well-established law lyophilization in the freeze drying box of lyophilization unit.To medicine solid residue moisture for being less than 2%, dimercaprol residual quantity is less than 0.2%, and Residual ethanol is 0%.Vacuum tamponade, rolls lid, and be up to the standards laggard storehouse.Make lyophilized injection.This lyophilized injection maybe can be made into aseptic spray.
7, under 100 grades of sterilization grade, the Lipid pharmaceutical granule being greater than 150nm that the filter membrane 6th step filtered retained is washed in the freshly prepd xylitol solution qualified by the 1st step operation sterilizing depyrogenation of 10%, measure the content of total phospholipids raw material in medicinal liquid, and with the qualified 10% xylitol solution adjustment medicine liquid volume of sterilizing depyrogenation, reach and to control in medicinal liquid total phospholipids content at 40-80mg/ml.Medicinal liquid is joined in another batching filling, under rushing nitrogen, 100 revs/min of mixing speeds, 50 are heated in 30-60 minute ± DEG C, keep this temperature range to stir 60-120 minute, then under keeping rushing nitrogen, 100 revs/min of rotating speeds, cooling medicinal liquid, to 20-25 DEG C, is dispensed into Pharmaceutical in the rustless steel pallet of 316L, is put in the freeze drying box of another lyophilization unit, well-established law lyophilization, to medical solid, moisture is less than 2%, and dimercaprol residual quantity is 0.2%, and Residual ethanol is 0%.Obtain liposome medicament solid, liposome medicament solid under 100 grades of sterilization grade, be crushed to 80-100 orders, the dosage allowed by pharmaceutics, well-established law makes the aseptic enteric oral preparation of this medicine, asepticly fastens agent.
8, all operations all should carry out in strict accordance with injection sterility requirements in national GMP specification.Oral formulations also must be undertaken by injection sterility requirements.
Embodiment 12
Crude drug is that each material component mole ratio of the liposome composite medicine specification that water solublity is strong is as follows:
The specification preparation process of the present embodiment and method are with embodiment 11.
Embodiment 13
Crude drug is that each material component mole ratio of the liposome composite medicine specification that water solublity is strong is as follows:
The specification preparation process of the present embodiment and method are with embodiment 11.
Embodiment 14
Crude drug is that each material component mole ratio of the liposome composite medicine specification that water solublity is strong is as follows:
The specification preparation process of the present embodiment and method are with embodiment 11.
Embodiment 15
Crude drug is that each material component mole ratio of the liposome composite medicine specification that water solublity is strong is as follows:
The specification preparation process of the present embodiment and method are with embodiment 11.
Embodiment 16
Crude drug is that each material component mole ratio of the liposome composite medicine specification that water solublity is strong is as follows:
The specification preparation process of the present embodiment and method are with embodiment 11.
Embodiment 17
Crude drug is that each material component mole ratio of the liposome composite medicine specification that water solublity is strong is as follows:
The specification preparation process of the present embodiment and method are with embodiment 11.
Embodiment 18
Crude drug is that each material component mole ratio of the liposome composite medicine specification that water solublity is strong is as follows:
The specification preparation process of the present embodiment and method are with embodiment 11.
Embodiment 19
Crude drug is that each material component mole ratio of the liposome composite medicine specification that water solublity is strong is as follows:
The specification preparation process of the present embodiment and method are with embodiment 11.
Embodiment 20
Crude drug is that each material component mole ratio of the liposome composite medicine specification that water solublity is strong is as follows:
The specification preparation process of the present embodiment and method are with embodiment 11.
Water miscible crude drug described in embodiment 11 to embodiment 20: preferably ganciclovir or cytosine arabinoside or sodium nitroprusside or valaciclovir or doxorubicin or etoposide or ligustrazine microcosmic salt or levofloxacin hydrochloride or a head born of the same parents amine sodium or Ondansetron Hydrochloride or meropenem.
Technological Economy and quality index contrast
Conclusion: the technology of the present invention prepares liposome medicine carrying body compared with existing homogeneous freeze-drying, fluidized bed coating law technology liposome medicine carrying body, the technology of the present invention economy and primary quality measure are all superior to homogeneous freeze-drying, and quality index is all better than fluidized bed coating.
Pharmacodynamics demonstration test:
1, medicament for anti-gastric ulcer pharmacodynamics demonstration test: laboratory animal selects Jiankang rat, male or female, body weight 200-250g, often organizes 8.Medicine and dosage is used to see result of the test table.Before experiment, Rat Fast 24 hours, freely drinks water, under etherization open abdominal cavity, the glass tubing of internal diameter 5mm, long 30mm is vertically positioned on body of stomach serosal surface, in tube chamber, adds glacial acetic acid 0.2ml, glacial acetic acid is dipped in out with cotton swab, suture operation otch after 1.5 minutes.Postoperative normal diet, within second day, set up blank group 1 group and positive controls 1 group at random, blank group saline administration, 0.5ml/ time, intraperitoneal injection, positive controls, with famotidine physiological saline solution, is got 0.5ml/ time, and liposome medicament administration group of the present invention establishes drug administration by injection, oral administration group.Liposome medicament drug administration by injection, uses physiological saline solution liposome medicament, gets 0.5ml/ time.Administration 15 days, administration every day 2 times, 12 hours once.Be divided into drug administration by injection and Kou take Give medicine.Every embodiment is made sample and is connected administration respectively 3 days.Administration, after 15 days, is dissected and is taken out stomach, and fix with formaldehyde, measures ulcer area mm
2, calculate each group of average ulcer area.
Results of pharmacodynamic test table:
Visible, said medicine of the present invention is higher than contrast positive drug curative effect.
2, anti-infectives pharmacodynamics test:
(1) animal is selected: the mice selecting the animalbioassay model prepared by Experimental Animal Center, body weight 18-22g, male and female half and half, random packet, every treated animal 50.
(2) infection bacteria species: model mice two groups that staphylococcus aureus causes the model mice of pneumonia, streptococcus pneumoniae causes pneumonia.
(3) infection dosage: 100% minimum lethal dose (100%MLD) being measured tested bacterial strain by Experimental Animal Center, as infection dosage.
(4) route of infection: bacterium stock solution 5% gastric Mucin is diluted to desired concn (Experimental Animal Center is determined), through tail vein injection.
(5) test method: mice is divided: model mice group two groups that A. staphylococcus aureus causes the model mice group of pneumonia, B. streptococcus pneumoniae causes pneumonia.Carry out not administration contrast, clindamycin phosphate for injection prepared by prior art contrast, drug control of the present invention.Every group model animal 50.Bolos intravenous administration or oral immediately after infection, was administered once every 6 hours again.Observe the reaction of animal thing, continuous 7 days, record dead mouse number.Medicine used and dosage, effect are shown in result of the test table:
3,1 myocardial ischemic antagonist pharmacodynamics demonstration test:
Select healthy mice, male or female, body weight 18-20g, often organize 10.Mouse cardiac muscle ischemia (preparing myocardial ischemia mouse model by Experimental Animal Center) is caused with isoproterenol.If blank and positive drug control group.Positive control medicine is defined as nitroglycerin, and every day is administered once, administration 10 days.The double staining of ischemia or infarcted myocardium is carried out, i.e. N-BT or TTC dyeing after 10 days; Under microscope, quantitative myocardial ischemia and infarct size, calculate the percent of every cell mean and positive control cell mean and the ratio with blank cell mean.Medicine used, dosage, administering mode are shown in results of pharmacodynamic test table:
3, the pharmacodynamics test of 2 hypotensors:
Select spontaneous hypertensive rat (SHR), often organize 10, Renal vascular stenotic type rat, often organize 10.First survey control period blood pressure and the rhythm of the heart, when administration after blood pressure stabilization, within 3 hours, measure blood pressure respectively after first 2 hours of administration and administration, the administration phase is 2 weeks.Administration after 3 hours after blood pressure drops be effective to more than 20mmHg.Medicine used, dosage, medication are shown in results of pharmacodynamic test table:
4, antitumor drug pharmacodynamics test:
Select rat kind tumor model: watt gram carcinosarcoma (W256) type.Body weight 50-70g, every treated animal 10.If negative control group and positive controls.Negative control group injecting normal saline, positive controls adopts and now sells paclitaxel medicine.1 administration every day,
15 days treatment times.Drug withdrawal put to death animal after 24 hours, dissected and peeled off tumor block, claimed tumor weight.Calculating therapeutic evaluation formula is:
Tumor control rate %=(C-T)/C X100%
When suppression ratio is greater than 30%, effectively.Result of the test table:
| Project | Tumor control rate % | Remarks |
| Now sell paclitaxel injection 50mg/kg lumbar injection | 70 | |
| Embodiment 11-16 ifosfamide 500mg/kg lumbar injection | 75 | |
| Embodiment 1-5 paclitaxel and Alprostadil 50mg/kg lumbar injection | 88 | |
| Embodiment 11-15 cytosine arabinoside 2mg/kg lumbar injection | 83 | |
| Embodiment 16-20 hydroxy camptothecin 8m/kg lumbar injection | 78 | |
| Embodiment 16-20 doxorubicin 20mg/kg lumbar injection | 81 | |
| Embodiment 16-20 etoposide 100mg/kg lumbar injection | 82 | |
| Embodiment 6-10 mitoxantrone 20mg/kg lumbar injection | 78 | |
| Embodiment 11-15 Ondansetron Hydrochloride 8mg/kg lumbar injection | Emesis rate 95% | Only tumor medicine causes vomiting |
| Embodiment 15-20 water soluble vitamins 100mg/kg lumbar injection | Effective percentage 100% | Tumour patient supplementary |
5, hypoglycemic medicine pharmacodynamics test: medicine of the present invention stimulates insulin secretion, so select normal health white mice, often organizes 15.Laboratory mouse is in fasting (can freely drink water) administration after 5 hours, and every day is administered once.Administration got blood after 2 hours, measured serum glucose values.Connect administration 7 days.Calculate blood glucose average rate of decrease (with blank group ratio).Blood glucose rate of descent is greater than 20% effective.Medicine used and dosage, route of administration are shown in result of the test table:
6, antiviral agents pharmacodynamics test:
Mice encephalitis model: mice 11-13g body weight, male and female regardless of, often organize 15.HSV-1 type Sm44 strain, viral lumbar injection, can cause encephalitis death, calculates LD
50.HSV-1 virus abdominal cavity injecting virus dosage LD successively again
01/2, each 2 days of 1/4,1/8 dosage, once a day.Calculate mortality rate, on average life number of days, contrast disease with medication therapy groups and to die protective rate, extending life rate.Treatment group administration 15 days, every day 2 times.Medicine used, dosage, route of administration are shown in result of the test table:
7, antifungal agent pharmacodynamics test: select healthy mice, body weight 18-20g, male and female half and half.Random packet, 6 groups, after infection immediately with 6 hours after tail vein injection administration, often organize 10, be used as systemic infection mycosis model.The strain of cryptococcus encephalitis fungus is adopted to make infection strain.First measure 100% minimum lethal dose (100%MLD) of made bacterial strain to mice as infection dosage.After infection immediately with 6 hours after tail vein injection administration, face connects administration 7 days, and record mortality of animals % compares with blank group.
Result of the test is as follows:
Visible by above-mentioned results of pharmacodynamic test, liposome composite medicine medicine of the present invention sells corresponding medicine in safety, stability, curative effect showing of being better than prepared by prior art all comprehensively.
Claims (5)
1. a pioglitazone liposome composite medicine, is characterized in that, pioglitazone liposome composite medicine nanometer particle size lyophilized injection, or the aseptic enteric oral preparation of pioglitazone liposome composite medicine; The proportioning of the molal quantity of each component raw material of pioglitazone liposome composite medicine nanometer particle size lyophilized injection and pioglitazone liposome composite medicine aseptic enteric oral preparation is as follows:
The mean molecule quantity of lecithin materials all defines and calculates with 800D, and lecithin materials is the compositions of hydrogenated soy phosphatidyl choline and polyene phosphatidylcholine, and mole ratio is the compositions of 1-5:0.5;
The antioxidant of phospholipid is reduced glutathion;
Phospholipid dispersions, or claim immobilized artificial membrane dispersant, or claim immobilized artificial membrane molecular state diluent, being again antioxidant, is dimercaprol;
Liposome medicine carrying body dispersant is again excipient, is xylitol, xylitol is except the amount of above-mentioned molal quantity proportioning, as pioglitazone liposome composite medicine nanometer particle size lyophilized injection with outward, also to use as the aseptic enteric oral preparation of pioglitazone liposome composite medicine by following provisions recruitment: the xylitol solution of 10% is that phosphate buffer makes solvent, xylitol amount and phosphate solution amount all should be determined according to the liposome medicament amount being greater than 150nm particle diameter, newly increase, exceed 10% xylitol solution of the amount in above-mentioned formula, the Lipid pharmaceutical being greater than 150nm particle diameter is scattered in sterilizing, in the 10% freshly prepd xylitol solution that depyrogenation is qualified, measure the content being greater than the particle diameter liposome medicament total phospholipids raw material of 150nm in liposome medicament dispersion medicinal liquid, and adjust medicine liquid volume with qualified freshly prepd 10% xylitol solution of sterilizing depyrogenation, reach and to control in medicinal liquid total phospholipids content at 40-80mg/ml, refer to (7) step of preparation method,
Surfactant is sodium dehydrocholate;
The normalized process for preparing of pioglitazone liposome composite medicine:
(1) by pioglitazone liposome composite medicine nanometer particle size lyophilized injection xylitol dosage, the weight percent solution of 10% of xylitol is dissolved in injection phosphorus phthalate buffer, by this solution 121 DEG C of steam sterilizations 20 minutes, when solution temperature is 20-25 DEG C, with the ultrafiltration post ultrafiltration of the ultrafilter membrane of molecular cut off 1000D, except the pyrogen in solution and pyrogen molecule fragment, get the solution that ultrafiltration obtains; Again at room temperature, the solution that decile ultrafiltration obtains, be divided into A, B solution, A, B solution are used respectively the analytical pure sodium hydroxide solution adjust pH 8.5 of 5%-8%, by A, B solution respectively through the membrane filtration mistake in less than 0.05 μm aperture, remove the precipitate of insoluble particle, high volence metal ion, metal ion, then be 5.0-8.0 with the analytically pure hydrochloric acid solution adjust pH of 8% respectively by A, B solution;
(2) by solution A in the spray dryer preparing pharmaceutical injection agent level, by spraying dry well-established law, solution A by the spraying nozzle at equipment top with cleanliness factor 100 grades of compressed airs, by compressor come, room temperature, mixing ejection, the temperature entered with device bottom 150 DEG C of-190 DEG C of 100 grades of pure airs, are attracted by air-introduced machine, high temperature, gas-liquid counter current mixes, and is spray dried to 120-150 order left and right porous granule dry powder; Dry complete, it is for subsequent use that dried material leaves this device bottom in;
(3) stirring and dissolving in fat-soluble crude drug pioglitazone, phospholipid, phospholipid dispersions dimercaprol to ethanol is added respectively complete, make proportion 1.0 to 1.2 solution, through the membrane ultrafiltration of molecular cut off 1000D, again through less than 0.05 μm aperture membrane filtration mistake, except pyrogen removal, antibacterial, insoluble particle;
(4) the composition dries granule of the solution A (2) step prepared, is put in boiling seed-coating machine, by boiling coating and the operation of airpillow-dry well-established law, first divides three parts by phospholipid alcoholic solution equal-volume prepared by (3) step, introducing is changed into anhydrous in device bottom, aseptic, without oil, without the room temperature purity nitrogen air-flow of the particle of more than 0.001 μm particle diameter, at 40 DEG C of-65 DEG C of temperature, coating under boiling fluidized state is carried out to the dry thing particle of the xylose that (2) step is obtained: first by the phospholipid alcoholic solution of 1/3rd volumes of first part, by being that 100 grades of pure nitrogen gas mix with compressed clean rank in the coating nozzle in the middle part of transport pump to equipment, being sprayed onto boiling in machine in spray form is highly the thick of 400mm-450mm material xylitol stream, at boiling material particle surface coating, material simultaneous altitude under boiling is mixed and dispersion equably, and make solvent volatilize as quick as thought, form porosu solid coating thin layer, the alcoholic solution feed liquid coating of first three/monophosphatide completes, airpillow-dry 15 minutes, the B solution first step prepared again is decile three parts also, by 1/3rd solution of the volume of first part of B solution anhydrous, aseptic, without oil, in 100 grades of purity nitrogen air-flows without the particle of more than 0.001 μm particle diameter, by aforesaid operations coating, after coating, airpillow-dry 20 minutes, carry out first time coating-drying process like this, repeat above-mentioned coating-drying process, the solution carrying out 1/3rd volumes of second part of second, third time two kinds of solution, the 3rd part respectively, by aforesaid operations, carries out the alternately coating-drying process of phospholipid liquid and B solution, outermost layer coatings is the dry nitride layer of xylitol micropore, for the third time after coating, and residual moisture content≤1.0% in the coating dried material obtained, residual dimercaprol≤0.2%,
(5) in material-compound tank, add the isopyknic water for injection of injection phosphorus acid salt solution with the first step, in tank, inflated with nitrogen and tank external pressure maintain an equal level, and under 100 revs/min of mixing speeds, are heated to 60 ± 5 DEG C; Tune speed of agitator is 500-700 rev/min, in tank under inflated with nitrogen, in 30 minutes to 60 minutes, dry for coating obtained for the 4th step thing is joined in material-compound tank; After adding the dry thing of coating, in tank under inflated with nitrogen environment, keep temperature 60 ± 5 DEG C, and keep 60-120 minute under stirring at 100 revs/min; Under stirring at 100 revs/min again, tank inner liquid medicine is cooled to 30-40 DEG C; Under stirring at 100 revs/min again, add antioxidant glutathion and sodium dehydrocholate respectively and dissolve completely, and adjust medicinal liquid pH value 5.0-8.0;
(6) keeping fluid temperature within the scope of 30 ± 5 DEG C, under 0.1-0.2Mpa nitrogen pressure, crossing the obtained medicinal liquid of (5) step by 0.15 μm of membrane filtration, getting the medicinal liquid of filtration, obtain the liposome medicinal liquid that particle diameter is less than 150nm; Allow the dosage subpackage liposome medicinal liquid of this medicine in cillin bottle by pharmaceutics, and partly jump a queue, well-established law lyophilization in the freeze drying box of lyophilization unit; To medicine solid residue moisture for being less than 2%, dimercaprol residual quantity is for being less than 0.2%, and vacuum tamponade, rolls lid, and be up to the standards laggard storehouse; Make the lyophilized injection of the nanometer particle size of liposome medicine carrying body; This lyophilized injection also can be made into aseptic spray;
(7) under 100 grades of sterilization grade, the Lipid pharmaceutical granule being greater than 150nm that the filter membrane (6) step filtered retained is washed by the 1st step operation, sterilizing, freshly prepd 10% xylitol solution of depyrogenation; The standby definition of this brand-new: the xylitol solution of 10% is that phosphate buffer makes solvent, xylitol amount and phosphate liquid measure all should be determined according to the liposome medicament amount being greater than 150nm particle diameter, it is 10% xylitol solution that newly increase, the amount exceeded in formula, measure the content of total phospholipids raw material in medicinal liquid, and with the qualified freshly prepd 10% xylitol solution adjustment medicine liquid volume of sterilizing depyrogenation, reach and to control in medicinal liquid total phospholipids content at 40-80mg/ml; This medicinal liquid is joined in another batching filling, and under rushing nitrogen, 100 revs/min of mixing speeds, are heated to 50 ± 5 DEG C in 30-60 minute, keep this temperature range to stir 60-120 minute; Under keeping rushing nitrogen again, 100 revs/min of rotating speeds, cooling medicinal liquid is to 20-25 DEG C, and medicinal liquid is dispensed in the rustless steel pallet of 316L, and be put in the freeze drying box of another lyophilizing unit, well-established law lyophilization, to medical solid, moisture is less than 2%; Dimercaprol residual quantity is for being less than 0.2%; Obtain liposome medicament solid, liposome medicament solid under 100 grades of sterilization grade, be crushed to 80-100 orders, the dosage allowed by pharmaceutics, well-established law makes the aseptic enteric oral preparation of this medicine, asepticly fastens agent.
2., according to the normalized process for preparing of pioglitazone plastid composition of medicine according to claim 1, it is characterized in that, in manufacturing step: (1) step is dissolving ultrafiltration; (2) step is spraying dry; (3) step portion is molecular dispersion and ultrafiltration; (4) step is molecule dispersion coating; (5) step is that aquation pelletize adds antioxidant; (6) step is lyophilization lyophilized injection; (7) step is lyophilization donsole formulation; Be summarized as: the method for the preparation of industrialization liposome medicament of dissolving ultrafiltration-spray drying-molecule dispersion coating-hydration palletizing-cryodesiccated molecular dispersion method.
3. according to pioglitazone liposome composite medicine according to claim 1, it is characterized in that, the dosage allowed by pharmaceutics, makes the lyophilized injection of pioglitazone liposome composite medicine, or is mixed with spray by well-established law again.
4. according to pioglitazone liposome composite medicine according to claim 1, it is characterized in that, pioglitazone liposome composite medicine is the aseptic enteric oral preparation of the pioglitazone liposome composite medicine that pharmaceutics allows, or the aseptic suppository of pioglitazone liposome composite medicine.
5., according to a kind of pioglitazone liposome composite medicine according to claim 1, it is characterized in that, its industrialization manufactures the combination that equipment used is dissolving tank-ultrafiltration post-spray dryer-boiling seed-coating machine-freezer dryer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310524614.5A CN104324004A (en) | 2010-07-29 | 2011-07-28 | Pioglitazone liposome combination drug and its large-scale industrial production process |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010240184.0 | 2010-07-29 | ||
| CN2010102401840A CN101912363A (en) | 2010-07-29 | 2010-07-29 | Dissolving ultrafiltration-spray drying-molecule dispersion coating-hydration palletizing-freeze drying method for preparing liposome combination medicine |
| CN201310524614.5A CN104324004A (en) | 2010-07-29 | 2011-07-28 | Pioglitazone liposome combination drug and its large-scale industrial production process |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011102121399A Division CN102697726A (en) | 2010-07-29 | 2011-07-28 | Liposome combined medicament of alprostadil and like and large-scale industrial production technology and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104324004A true CN104324004A (en) | 2015-02-04 |
Family
ID=43320121
Family Applications (44)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102401840A Pending CN101912363A (en) | 2010-07-29 | 2010-07-29 | Dissolving ultrafiltration-spray drying-molecule dispersion coating-hydration palletizing-freeze drying method for preparing liposome combination medicine |
| CN2011101525380A Pending CN102218034A (en) | 2010-07-29 | 2011-06-09 | Formula, preparation method and use of azithromycin liposome combined medicament |
| CN2011101525304A Pending CN102218033A (en) | 2010-07-29 | 2011-06-09 | Formula, preparation method and use of alprostadil liposome combined medicament |
| CN2011101525018A Pending CN102218031A (en) | 2010-07-29 | 2011-06-09 | Formula, preparation method and use of lactose-azithromycin liposome combined medicine |
| CN2011101523652A Pending CN102258472A (en) | 2010-07-29 | 2011-06-09 | Combined medicament formulation of cefuroxime sodium liposome, preparation method and applications thereof |
| CN201110152561XA Pending CN102218036A (en) | 2010-07-29 | 2011-06-09 | Formula, preparation method and application of omeprazole sodium liposome composite medicament |
| CN2011101524867A Pending CN102218029A (en) | 2010-07-29 | 2011-06-09 | Formula, preparation method and use of pefloxacin mesylate liposome combined medicament |
| CN2011101525130A Pending CN102228435A (en) | 2010-07-29 | 2011-06-09 | Water-soluble vitamin liposome pharmaceutical composition formula and preparation method and application thereof |
| CN2011101525249A Pending CN102218032A (en) | 2010-07-29 | 2011-06-09 | Formula, preparation method and application of lansoprazole liposome composite medicament |
| CN2011101525499A Pending CN102218035A (en) | 2010-07-29 | 2011-06-09 | Formula of combined medicament of esomeprazole sodium liposomes, method for preparing same and application thereof |
| CN2011101524903A Pending CN102218030A (en) | 2010-07-29 | 2011-06-09 | Formula, preparation method and application of pantoprazole sodium liposome composite medicament |
| CN2011101541364A Pending CN102247579A (en) | 2010-07-29 | 2011-06-10 | Formula, preparation method and application of Xingnaojing lipidosome combined drug |
| CN2011101541294A Pending CN102218037A (en) | 2010-07-29 | 2011-06-10 | Ifosfamide liposome combination medicament, and formula, preparation method and purpose thereof |
| CN2011101541383A Pending CN102218039A (en) | 2010-07-29 | 2011-06-10 | Formula, preparation method and use of potassium sodium dehydroandroan drographolide succinate liposome combined medicament |
| CN2011101541379A Pending CN102218038A (en) | 2010-07-29 | 2011-06-10 | Formula, preparation method and application of tolazoline hydrochloride liposome combination medicine |
| CN201310478836.8A Pending CN103919727A (en) | 2010-07-29 | 2011-07-28 | Fluconazole liposome combination drug and large-scale industrialized production technology and purpose |
| CN201310521905.9A Pending CN104323996A (en) | 2010-07-29 | 2011-07-28 | Ligustrazine phosphate liposome composite medicine and its large-scale production process and use |
| CN201310521849.9A Pending CN104323995A (en) | 2010-07-29 | 2011-07-28 | Cefpiramide sodium liposome combined drug and large-scale production process and application thereof |
| CN201310524536.9A Pending CN104324002A (en) | 2010-07-29 | 2011-07-28 | Rosiglitazone liposome combination drug and its large-scale industrial production process and application |
| CN201310535496.8A Pending CN104337827A (en) | 2010-07-29 | 2011-07-28 | Compound ribavirin liposome combination drug and its large-scale industrial production process and application |
| CN201310481198.5A Pending CN103816160A (en) | 2010-07-29 | 2011-07-28 | Compound cefuroxime axetil liposome composite drug, and large-scale industrial production process and application thereof |
| CN201310475667.2A Pending CN103919722A (en) | 2010-07-29 | 2011-07-28 | Doxorubicin liposome combination drug and large-scale industrialized production technology and purpose |
| CN201310520919.9A Pending CN104323994A (en) | 2010-07-29 | 2011-07-28 | Sodium nitroprusside liposome combined medicine and large-scale production process and application thereof |
| CN201310520448.1A Pending CN104337765A (en) | 2010-07-29 | 2011-07-28 | Meropenem liposome combination drug and its large-scale industrial production process and application |
| CN201310475983.XA Pending CN103919724A (en) | 2010-07-29 | 2011-07-28 | Baicalein liposome combination drug and large-scale industrialized production technology and purpose |
| CN201310475696.9A Pending CN103919723A (en) | 2010-07-29 | 2011-07-28 | Adefovir dipivoxil liposome combination drug and large-scale industrialized production technology and purpose |
| CN201310475640.3A Pending CN103919721A (en) | 2010-07-29 | 2011-07-28 | Hydroxycamptothecin liposome combination drug and large-scale industrialized production technology and purpose |
| CN201310522311.XA Pending CN104323999A (en) | 2010-07-29 | 2011-07-28 | Clindamycin Phosphate Plastid Combination Medicine and Its Large-scale Industrialized Production Process and Application |
| CN201310522901.2A Pending CN104324000A (en) | 2010-07-29 | 2011-07-28 | Etoposide liposome combination drug and its large-scale industrial production process and application |
| CN201310522276.1A Pending CN104323998A (en) | 2010-07-29 | 2011-07-28 | Ganciclovir liposome combination drug and its large-scale industrial production process and application |
| CN201310481188.1A Pending CN103768019A (en) | 2010-07-29 | 2011-07-28 | Compound alprostadil lipidosome combined drug as well as large-scale industrial production process and application thereof |
| CN201310481236.7A Pending CN103768020A (en) | 2010-07-29 | 2011-07-28 | Compound taxol lipidosome combined drug, and large-scale industrial production process and application thereof |
| CN201310481190.9A Pending CN103919728A (en) | 2010-07-29 | 2011-07-28 | Prostaglandin A1 liposome combination drug and large-scale industrialized production technology and purpose |
| CN201310522915.4A Pending CN104323989A (en) | 2010-07-29 | 2011-07-28 | Voriconazole liposome combination drug and its large-scale industrial production process and application |
| CN201310524614.5A Pending CN104324004A (en) | 2010-07-29 | 2011-07-28 | Pioglitazone liposome combination drug and its large-scale industrial production process |
| CN201310478818.XA Pending CN103919726A (en) | 2010-07-29 | 2011-07-28 | Valacyclovir liposome combination drug and large-scale industrialized production technology and purpose |
| CN201310520781.2A Pending CN104323993A (en) | 2010-07-29 | 2011-07-28 | Ondansetron hydrochloride liposome combination drug and its large-scale industrial production process and application |
| CN2011102121399A Pending CN102697726A (en) | 2010-07-29 | 2011-07-28 | Liposome combined medicament of alprostadil and like and large-scale industrial production technology and application thereof |
| CN201310520821.3A Pending CN104352438A (en) | 2010-07-29 | 2011-07-28 | Tanshinone Ⅱ A liposome combination drug and its large-scale industrial production process and application |
| CN201310524596.0A Pending CN104324003A (en) | 2010-07-29 | 2011-07-28 | Cytarabine liposome combination drug and its large-scale industrial production process and application |
| CN201310524477.5A Pending CN104324001A (en) | 2010-07-29 | 2011-07-28 | Mitoxantrone liposome combination drug and its large-scale industrial production process and application |
| CN201310481216.XA Pending CN103784402A (en) | 2010-07-29 | 2011-07-28 | Isosorbide dinitrate liposome compound medicine and industrial production process and application thereof |
| CN201310475997.1A Pending CN103919725A (en) | 2010-07-29 | 2011-07-28 | Pazufloxacin mesilate liposome combination drug and large-scale industrialized production technology and purpose |
| CN201310522252.6A Pending CN104323997A (en) | 2010-07-29 | 2011-07-28 | Simvastatin liposome combined drug and large-scale production process and application thereof |
Family Applications Before (34)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102401840A Pending CN101912363A (en) | 2010-07-29 | 2010-07-29 | Dissolving ultrafiltration-spray drying-molecule dispersion coating-hydration palletizing-freeze drying method for preparing liposome combination medicine |
| CN2011101525380A Pending CN102218034A (en) | 2010-07-29 | 2011-06-09 | Formula, preparation method and use of azithromycin liposome combined medicament |
| CN2011101525304A Pending CN102218033A (en) | 2010-07-29 | 2011-06-09 | Formula, preparation method and use of alprostadil liposome combined medicament |
| CN2011101525018A Pending CN102218031A (en) | 2010-07-29 | 2011-06-09 | Formula, preparation method and use of lactose-azithromycin liposome combined medicine |
| CN2011101523652A Pending CN102258472A (en) | 2010-07-29 | 2011-06-09 | Combined medicament formulation of cefuroxime sodium liposome, preparation method and applications thereof |
| CN201110152561XA Pending CN102218036A (en) | 2010-07-29 | 2011-06-09 | Formula, preparation method and application of omeprazole sodium liposome composite medicament |
| CN2011101524867A Pending CN102218029A (en) | 2010-07-29 | 2011-06-09 | Formula, preparation method and use of pefloxacin mesylate liposome combined medicament |
| CN2011101525130A Pending CN102228435A (en) | 2010-07-29 | 2011-06-09 | Water-soluble vitamin liposome pharmaceutical composition formula and preparation method and application thereof |
| CN2011101525249A Pending CN102218032A (en) | 2010-07-29 | 2011-06-09 | Formula, preparation method and application of lansoprazole liposome composite medicament |
| CN2011101525499A Pending CN102218035A (en) | 2010-07-29 | 2011-06-09 | Formula of combined medicament of esomeprazole sodium liposomes, method for preparing same and application thereof |
| CN2011101524903A Pending CN102218030A (en) | 2010-07-29 | 2011-06-09 | Formula, preparation method and application of pantoprazole sodium liposome composite medicament |
| CN2011101541364A Pending CN102247579A (en) | 2010-07-29 | 2011-06-10 | Formula, preparation method and application of Xingnaojing lipidosome combined drug |
| CN2011101541294A Pending CN102218037A (en) | 2010-07-29 | 2011-06-10 | Ifosfamide liposome combination medicament, and formula, preparation method and purpose thereof |
| CN2011101541383A Pending CN102218039A (en) | 2010-07-29 | 2011-06-10 | Formula, preparation method and use of potassium sodium dehydroandroan drographolide succinate liposome combined medicament |
| CN2011101541379A Pending CN102218038A (en) | 2010-07-29 | 2011-06-10 | Formula, preparation method and application of tolazoline hydrochloride liposome combination medicine |
| CN201310478836.8A Pending CN103919727A (en) | 2010-07-29 | 2011-07-28 | Fluconazole liposome combination drug and large-scale industrialized production technology and purpose |
| CN201310521905.9A Pending CN104323996A (en) | 2010-07-29 | 2011-07-28 | Ligustrazine phosphate liposome composite medicine and its large-scale production process and use |
| CN201310521849.9A Pending CN104323995A (en) | 2010-07-29 | 2011-07-28 | Cefpiramide sodium liposome combined drug and large-scale production process and application thereof |
| CN201310524536.9A Pending CN104324002A (en) | 2010-07-29 | 2011-07-28 | Rosiglitazone liposome combination drug and its large-scale industrial production process and application |
| CN201310535496.8A Pending CN104337827A (en) | 2010-07-29 | 2011-07-28 | Compound ribavirin liposome combination drug and its large-scale industrial production process and application |
| CN201310481198.5A Pending CN103816160A (en) | 2010-07-29 | 2011-07-28 | Compound cefuroxime axetil liposome composite drug, and large-scale industrial production process and application thereof |
| CN201310475667.2A Pending CN103919722A (en) | 2010-07-29 | 2011-07-28 | Doxorubicin liposome combination drug and large-scale industrialized production technology and purpose |
| CN201310520919.9A Pending CN104323994A (en) | 2010-07-29 | 2011-07-28 | Sodium nitroprusside liposome combined medicine and large-scale production process and application thereof |
| CN201310520448.1A Pending CN104337765A (en) | 2010-07-29 | 2011-07-28 | Meropenem liposome combination drug and its large-scale industrial production process and application |
| CN201310475983.XA Pending CN103919724A (en) | 2010-07-29 | 2011-07-28 | Baicalein liposome combination drug and large-scale industrialized production technology and purpose |
| CN201310475696.9A Pending CN103919723A (en) | 2010-07-29 | 2011-07-28 | Adefovir dipivoxil liposome combination drug and large-scale industrialized production technology and purpose |
| CN201310475640.3A Pending CN103919721A (en) | 2010-07-29 | 2011-07-28 | Hydroxycamptothecin liposome combination drug and large-scale industrialized production technology and purpose |
| CN201310522311.XA Pending CN104323999A (en) | 2010-07-29 | 2011-07-28 | Clindamycin Phosphate Plastid Combination Medicine and Its Large-scale Industrialized Production Process and Application |
| CN201310522901.2A Pending CN104324000A (en) | 2010-07-29 | 2011-07-28 | Etoposide liposome combination drug and its large-scale industrial production process and application |
| CN201310522276.1A Pending CN104323998A (en) | 2010-07-29 | 2011-07-28 | Ganciclovir liposome combination drug and its large-scale industrial production process and application |
| CN201310481188.1A Pending CN103768019A (en) | 2010-07-29 | 2011-07-28 | Compound alprostadil lipidosome combined drug as well as large-scale industrial production process and application thereof |
| CN201310481236.7A Pending CN103768020A (en) | 2010-07-29 | 2011-07-28 | Compound taxol lipidosome combined drug, and large-scale industrial production process and application thereof |
| CN201310481190.9A Pending CN103919728A (en) | 2010-07-29 | 2011-07-28 | Prostaglandin A1 liposome combination drug and large-scale industrialized production technology and purpose |
| CN201310522915.4A Pending CN104323989A (en) | 2010-07-29 | 2011-07-28 | Voriconazole liposome combination drug and its large-scale industrial production process and application |
Family Applications After (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310478818.XA Pending CN103919726A (en) | 2010-07-29 | 2011-07-28 | Valacyclovir liposome combination drug and large-scale industrialized production technology and purpose |
| CN201310520781.2A Pending CN104323993A (en) | 2010-07-29 | 2011-07-28 | Ondansetron hydrochloride liposome combination drug and its large-scale industrial production process and application |
| CN2011102121399A Pending CN102697726A (en) | 2010-07-29 | 2011-07-28 | Liposome combined medicament of alprostadil and like and large-scale industrial production technology and application thereof |
| CN201310520821.3A Pending CN104352438A (en) | 2010-07-29 | 2011-07-28 | Tanshinone Ⅱ A liposome combination drug and its large-scale industrial production process and application |
| CN201310524596.0A Pending CN104324003A (en) | 2010-07-29 | 2011-07-28 | Cytarabine liposome combination drug and its large-scale industrial production process and application |
| CN201310524477.5A Pending CN104324001A (en) | 2010-07-29 | 2011-07-28 | Mitoxantrone liposome combination drug and its large-scale industrial production process and application |
| CN201310481216.XA Pending CN103784402A (en) | 2010-07-29 | 2011-07-28 | Isosorbide dinitrate liposome compound medicine and industrial production process and application thereof |
| CN201310475997.1A Pending CN103919725A (en) | 2010-07-29 | 2011-07-28 | Pazufloxacin mesilate liposome combination drug and large-scale industrialized production technology and purpose |
| CN201310522252.6A Pending CN104323997A (en) | 2010-07-29 | 2011-07-28 | Simvastatin liposome combined drug and large-scale production process and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (44) | CN101912363A (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101912363A (en) * | 2010-07-29 | 2010-12-15 | 蔡海德 | Dissolving ultrafiltration-spray drying-molecule dispersion coating-hydration palletizing-freeze drying method for preparing liposome combination medicine |
| CN101912364B (en) * | 2010-08-09 | 2015-07-15 | 刘会梅 | Ginkgolide B liposome medicinal composition |
| CN102988290B (en) * | 2012-12-06 | 2014-10-22 | 北京泰德制药股份有限公司 | PGA1 ((13E,15S)-15-hydroxy-9-oxo-prosta-10,13-dien-1-oic acid)-containing lipid emulsion and preparation method thereof |
| US20140275122A1 (en) | 2013-03-14 | 2014-09-18 | Fresenius Kabi Usa, Llc | Voriconazole Formulations |
| CN104474525A (en) * | 2014-06-09 | 2015-04-01 | 邓学峰 | Cerebroprotein hydrolysate combinatorial drug and preparation method thereof |
| CN104306342B (en) * | 2014-10-10 | 2018-04-13 | 河北科技大学 | A kind of baicalein freeze-dried powder injection |
| CN105859642B (en) * | 2016-04-19 | 2018-07-31 | 齐鲁工业大学 | A kind of method for extraction and purification of Tetramethylpyrazine |
| CN106074597A (en) * | 2016-06-13 | 2016-11-09 | 中山大学 | Sodium nitroprusside is as the purposes of indole amine 2,3-dioxygenase-1 inhibitor |
| CN111195236B (en) * | 2018-11-19 | 2022-03-15 | 浙江长典药物技术开发有限公司 | Preparation method of meropenem for injection |
| CN111198232A (en) * | 2018-11-19 | 2020-05-26 | 浙江长典医药有限公司 | Detection method of meropenem for injection |
| CN109432007A (en) * | 2018-12-05 | 2019-03-08 | 嘉兴学院 | Etoposide nanometer passs release system and preparation method thereof |
| CN111053744B (en) * | 2018-12-27 | 2021-12-10 | 北京安德普泰医疗科技有限公司 | Baicalin liposome and application thereof |
| CN109481419B (en) * | 2019-01-16 | 2021-04-02 | 中国人民解放军陆军军医大学第一附属医院 | Rosiglitazone nano preparation and preparation method and application thereof |
| CN109793744B (en) * | 2019-03-26 | 2020-12-18 | 牡丹江医学院 | A kind of pharmaceutical composition for interventional treatment of uterine fibroids and preparation method thereof |
| CN109966251A (en) * | 2019-04-11 | 2019-07-05 | 成都大学 | Drug for inhibiting choroidal neovascularization and preparation method and drug efficacy test method |
| CN110051654A (en) * | 2019-04-19 | 2019-07-26 | 天津中医药大学 | The ophthalmically acceptable lipid nano particle preparation of baicalein and preparation method thereof of N- trimethyl chitin modification |
| CN110898004B (en) * | 2019-12-20 | 2020-12-11 | 健进制药有限公司 | Cytarabine injection preparation and preparation process thereof |
| CN115279344A (en) * | 2020-03-12 | 2022-11-01 | 石药集团中奇制药技术（石家庄）有限公司 | Application of mitoxantrone hydrochloride liposome |
| CN113750033B (en) * | 2021-09-23 | 2023-09-15 | 成都医学院 | Baicalin ethosome-loaded soluble hyaluronic acid microneedle array and preparation method and application thereof |
| CN119161415B (en) * | 2024-11-22 | 2025-01-21 | 山东第二医科大学 | Drug-loaded liposome compound containing polypeptide and preparation method and application thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4744989A (en) * | 1984-02-08 | 1988-05-17 | E. R. Squibb & Sons, Inc. | Method of preparing liposomes and products produced thereby |
| CN1686123A (en) * | 2005-04-19 | 2005-10-26 | 北京正大绿洲医药科技有限公司 | Pyrolidone hydrochloride drip pill and its preparation method |
| WO2007136129A1 (en) * | 2006-05-23 | 2007-11-29 | Takeda Pharmaceutical Company Limited | Oral preparation comprising pioglitazone |
| CN101156853A (en) * | 2007-09-27 | 2008-04-09 | 刘全胜 | Hydrochloric acid glitazone dispersion piece and its preparation method |
| WO2008093882A1 (en) * | 2007-02-01 | 2008-08-07 | Takeda Pharmaceutical Company Limited | Solid preparation comprising alogliptin and pioglitazone |
| WO2009075391A1 (en) * | 2007-12-13 | 2009-06-18 | Kyushu University, National University Corporation | Drug-containing nanoparticles |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3269611D1 (en) * | 1981-07-02 | 1986-04-10 | Hoffmann La Roche | Process for preparing liposome solutions |
| GB2135268A (en) * | 1983-02-15 | 1984-08-30 | Squibb & Sons Inc | Method of preparing liposomes and products produced thereby |
| US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| TW367324B (en) * | 1995-08-16 | 1999-08-21 | Ono Pharmaceutical Co | Prostaglandin derivatives |
| US5718917A (en) * | 1995-12-15 | 1998-02-17 | Harvard Scientific Corporation | PGE-1 containing lyophilized liposomes for use in the treatment of erectile dysfunction |
| WO1998033482A1 (en) * | 1997-02-04 | 1998-08-06 | Abbott Laboratories | Pain reducing parenteral liposome formulation |
| RU2111744C1 (en) * | 1997-03-20 | 1998-05-27 | Всероссийский научно-исследовательский институт ветеринарной вирусологии и микробиологии | Preparation abactan for treatment and prophylaxis of infectious sicknesses in animals |
| US6106858A (en) * | 1997-09-08 | 2000-08-22 | Skyepharma, Inc. | Modulation of drug loading in multivescular liposomes |
| IT1298575B1 (en) * | 1998-02-06 | 2000-01-12 | Vectorpharma Int | PHARMACEUTICAL COMPOSITIONS IN THE FORM OF NANOPARTICLES INCLUDING LIPID SUBSTANCES AND ANTIPHILIC SUBSTANCES AND RELATED PROCESS OF |
| MXPA01012912A (en) * | 1999-06-22 | 2002-09-18 | Boehringer Ingelheim Int | Stable xylometazoline and oxymetazoline solution. |
| KR100669507B1 (en) * | 2000-08-01 | 2007-01-16 | 보령제약 주식회사 | Manufacturing Method of Sepuloxime |
| CZ20031262A3 (en) * | 2000-10-16 | 2004-03-17 | Neopharm, Inc. | Liposomal formulation of mitoxantrone |
| CN1127986C (en) * | 2001-06-21 | 2003-11-19 | 中国人民解放军第二军医大学 | Process for preparing lipoid as precursor of medicine carrier |
| CN1449759A (en) * | 2002-04-10 | 2003-10-22 | 南阳普康集团化学制药厂 | Prostaglandin E1 liposome frozen dry powder injection and production technology thereof |
| US20030215493A1 (en) * | 2002-04-30 | 2003-11-20 | Patel Pravin M. | Composition and method for dermatological treatment |
| EP1506032A1 (en) * | 2002-05-20 | 2005-02-16 | Research Development Foundation | Aerosol drug inhibition of lung metastases |
| US20030235610A1 (en) * | 2002-06-21 | 2003-12-25 | Piedmont Pharmaceuticals, Llc | Liposomes containing biologically active compounds |
| CN1411803A (en) * | 2002-08-29 | 2003-04-23 | 四川大学 | Method for preparing precursor liposome and its device |
| CN1186011C (en) * | 2002-09-17 | 2005-01-26 | 西安力邦医药科技有限责任公司 | automatic liposome preparation apparatus and method for prepaving liplsome by same |
| US6702850B1 (en) * | 2002-09-30 | 2004-03-09 | Mediplex Corporation Korea | Multi-coated drug-eluting stent for antithrombosis and antirestenosis |
| SE0203065D0 (en) * | 2002-10-16 | 2002-10-16 | Diabact Ab | Gastric acid secretion inhibiting composition |
| US20040092735A1 (en) * | 2002-11-08 | 2004-05-13 | Orchid Chemicals & Pharmaceuticals Limited | Process for the preparation of cefuroxime sodium |
| US7691905B2 (en) * | 2002-12-24 | 2010-04-06 | New York University | Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (PABA) |
| CN1215839C (en) * | 2003-07-18 | 2005-08-24 | 中国药科大学 | Tanshinone solid lipid nanoparticles and preparation method thereof |
| CN1623538A (en) * | 2003-12-02 | 2005-06-08 | 刘力 | Tanshinone II A sulfonic acid or tanshinone II A sodium sulfonate freeze-dried powder injection and its preparation method |
| US20090060998A1 (en) * | 2004-01-14 | 2009-03-05 | Gilead Sciences, Inc. | Lipid-based dispersions useful for drug delivery |
| CN1669554A (en) * | 2004-03-17 | 2005-09-21 | 昆明希捷医药研发有限公司 | Liposome vitality conazole preparation |
| CN1563007A (en) * | 2004-04-07 | 2005-01-12 | 复旦大学 | 9-(2-fatty ester ethoxy methyl) guanine, liposome, and preparation emthod |
| CA2564542C (en) * | 2004-04-22 | 2012-11-27 | Celator Pharmaceuticals, Inc. | Combination formulations of anthracycline agents and cytidine analogs |
| CA2566559C (en) * | 2004-05-17 | 2014-05-06 | Inex Pharmaceuticals Corporation | Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof |
| CN1242740C (en) * | 2004-08-05 | 2006-02-22 | 常州太平洋药物研究所有限公司 | Mitoxantrone or mitoxantrone hydrochloride liposome injection and its preparing process |
| CN1745750A (en) * | 2004-09-11 | 2006-03-15 | 胡才忠 | Lansoprazole liposome and its preparation |
| JP4228230B2 (en) * | 2004-11-08 | 2009-02-25 | 独立行政法人産業技術総合研究所 | Method for producing liposome suspension and use using liposome |
| CN1660119A (en) * | 2004-12-22 | 2005-08-31 | 王剑 | Liposome combination of precursor of vitamine D3 and preparation method |
| DE102005002469B3 (en) * | 2005-01-18 | 2006-05-11 | Abnoba Heilmittel Gmbh | Encapsulation of substances in liposome comprises applying two different monolayers on porous carrier membrane; applying different fluid volumes on monolayers; bringing compressible membrane and lacing the dismantled area to liposome |
| CN1686125A (en) * | 2005-05-08 | 2005-10-26 | 北京正大绿洲医药科技有限公司 | Rogelinone drip pill and its preparation method |
| CN1751751A (en) * | 2005-09-07 | 2006-03-29 | 华北制药集团有限责任公司 | Immediate dispensing infusion |
| CN1977826A (en) * | 2005-11-23 | 2007-06-13 | 兰贝克赛实验室有限公司 | Method for increasing prodrug bioavailability using solid lipid nano granule |
| CN100506962C (en) * | 2005-12-09 | 2009-07-01 | 郭涛 | Garlic oil refining process and the Preparation process of its emulsion and solid nanometer liposome particle |
| US20070231390A1 (en) * | 2006-03-29 | 2007-10-04 | Andrx Labs, Llc | Formulations including hygroscopic compounds |
| CN100459978C (en) * | 2006-04-28 | 2009-02-11 | 广东药学院 | A kind of rosiglitazone sustained-release tablet and preparation method thereof |
| CN1951386A (en) * | 2006-06-05 | 2007-04-25 | 张宏宇 | Medicinal combinations composed by meropenem with three kinds of sputum removing medicament respectively |
| CN101091698A (en) * | 2006-06-22 | 2007-12-26 | 刘祥华 | New type antineoplastic medicine, and preparation method |
| CN101095659A (en) * | 2006-06-28 | 2008-01-02 | 蔡海德 | Liposome combined medicine and method for preparing the same |
| CN101108188A (en) * | 2006-07-17 | 2008-01-23 | 广州瑞济生物技术有限公司 | Novel long circulation alprostadil liposome drug feeding system for injection and method of preparing the same |
| CN1887271A (en) * | 2006-08-02 | 2007-01-03 | 刘祥华 | Azithromycin liposome composition medicine and its prepn process |
| CN1907266A (en) * | 2006-08-22 | 2007-02-07 | 刘祥华 | Potassium dehydroandrographolide succinate/potassium dehydroandrographolide succinate liposome composition and production method thereof |
| CN1915222B (en) * | 2006-09-18 | 2010-08-04 | 蔡海德 | Composition of liposome, and preparation method |
| US7976743B2 (en) * | 2006-10-16 | 2011-07-12 | Northwestern University | Gas-containing liposomes |
| CN100490807C (en) * | 2006-10-23 | 2009-05-27 | 石药集团欧意药业有限公司 | Cephalofruxin ester liposome, its preparation and medicinal composition containing it |
| CN100586430C (en) * | 2006-11-09 | 2010-02-03 | 刘祥华 | Paclitaxel/multialkene paclitaxel liposome composite medicine and preparation method thereof |
| CN100586421C (en) * | 2006-11-09 | 2010-02-03 | 刘祥华 | Ligustrazine microcosmic salt liposome medicine and preparing method |
| CN1973826A (en) * | 2006-12-18 | 2007-06-06 | 沈阳药科大学 | Injection containing lipoid microsphere of etoposide and its prepn process |
| CN101209243B (en) * | 2006-12-29 | 2010-12-08 | 石药集团中奇制药技术（石家庄）有限公司 | Liposome medicament and preparation thereof |
| CN101657098A (en) * | 2007-02-16 | 2010-02-24 | 切拉托尔制药公司 | The fixed drug ratios that is used for the treatment of hematopoiesis cancer and proliferative disorders |
| CN101019869B (en) * | 2007-03-09 | 2010-10-13 | 蔡海德 | Medicine composition of alprostadil and Chuanhuning/Yanhuning liposome and its preparation |
| GB0710277D0 (en) * | 2007-05-30 | 2007-07-11 | Univ Birmingham | Use of antivirals in the treatment of medical disorders |
| CN101322690A (en) * | 2007-06-12 | 2008-12-17 | 广州瑞济生物技术有限公司 | Stable medicament lipid complexes |
| CA2595485A1 (en) * | 2007-08-01 | 2009-02-01 | Bc Cancer Agency | Liposomal compositions for parenteral delivery of statins |
| CN101152178B (en) * | 2007-10-11 | 2010-10-06 | 蔡海德 | Sophoridine nano liposome medicament and preparation of the same |
| CN101152182A (en) * | 2007-10-17 | 2008-04-02 | 沈阳药科大学 | Nasal administration preparation of ligustrazine and preparation method thereof |
| CN101439034A (en) * | 2007-11-22 | 2009-05-27 | 沈阳沃森药物研究所 | Tanshinone IIA lipid complexes and micelle composition thereof for injection |
| KR100970911B1 (en) * | 2007-12-13 | 2010-07-20 | 재단법인서울대학교산학협력재단 | Semi-solid external preparations containing triazole antifungal agents and preparation method thereof |
| CN101524448B (en) * | 2008-03-04 | 2012-04-18 | 华东理工大学 | An analgesic and anti-inflammatory traditional Chinese medicine composition and its preparation method and application |
| CN101507708B (en) * | 2008-03-28 | 2011-01-19 | 中国人民解放军济南军区第四○一医院 | Preparation method of liposome |
| CN101273971A (en) * | 2008-05-09 | 2008-10-01 | 绍兴文理学院 | Etosome preparation of antifungal drug and preparation method thereof |
| EP2143422A1 (en) * | 2008-07-11 | 2010-01-13 | S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. | Ophthalmic compositions containing gemifloxacin for the treatment of ocular infections |
| CN101366698A (en) * | 2008-09-28 | 2009-02-18 | 中国药科大学 | Glycyrrhetinic acid proliposome with long circulation effect and preparation method thereof |
| KR20110095856A (en) * | 2008-12-01 | 2011-08-25 | 글레이드 올가닉스 프라이비트 리미티드 | Synergistic Combination of Aztreonam and Carbapenems, Meropenem and Ertafenem |
| CN101474155B (en) * | 2009-01-24 | 2011-03-16 | 重庆医科大学 | Lung-targeted medicine carrying precursor liposome for injection and method of use thereof |
| CN101491499B (en) * | 2009-02-19 | 2010-10-13 | 陶灵刚 | Composite liposome for injection containing 12 vitamins and preparation method thereof |
| CN101530393B (en) * | 2009-04-07 | 2010-10-13 | 王明 | Clindamycin phosphate lipidosome freeze-dried preparation |
| CN101658493B (en) * | 2009-09-09 | 2012-08-15 | 苏州纳康生物科技有限公司 | Azithromycin nanostructured lipid carrier and preparation method thereof |
| CN101703470B (en) * | 2009-11-17 | 2012-05-09 | 海南美兰史克制药有限公司 | Fluconazole liposome solid preparation and new application thereof |
| CN101721379B (en) * | 2009-11-19 | 2011-02-02 | 海南美兰史克制药有限公司 | Cefuroxime sodium suspension powder injection |
| CN101703469B (en) * | 2009-11-24 | 2011-10-19 | 东北农业大学 | Preparation method and products of danofloxacin mesylate liposome |
| CN101766571B (en) * | 2010-02-05 | 2011-09-14 | 王明 | Cefpiramide, sodium benzoate, sodium bicarbonate pharmaceutical composite lipidosome injection |
| CN101912363A (en) * | 2010-07-29 | 2010-12-15 | 蔡海德 | Dissolving ultrafiltration-spray drying-molecule dispersion coating-hydration palletizing-freeze drying method for preparing liposome combination medicine |
| CN101912364B (en) * | 2010-08-09 | 2015-07-15 | 刘会梅 | Ginkgolide B liposome medicinal composition |
| CN102091035A (en) * | 2010-08-20 | 2011-06-15 | 邓学峰 | Pefloxacin mesilate liposome medicine composition |
-
2010
- 2010-07-29 CN CN2010102401840A patent/CN101912363A/en active Pending
-
2011
- 2011-06-09 CN CN2011101525380A patent/CN102218034A/en active Pending
- 2011-06-09 CN CN2011101525304A patent/CN102218033A/en active Pending
- 2011-06-09 CN CN2011101525018A patent/CN102218031A/en active Pending
- 2011-06-09 CN CN2011101523652A patent/CN102258472A/en active Pending
- 2011-06-09 CN CN201110152561XA patent/CN102218036A/en active Pending
- 2011-06-09 CN CN2011101524867A patent/CN102218029A/en active Pending
- 2011-06-09 CN CN2011101525130A patent/CN102228435A/en active Pending
- 2011-06-09 CN CN2011101525249A patent/CN102218032A/en active Pending
- 2011-06-09 CN CN2011101525499A patent/CN102218035A/en active Pending
- 2011-06-09 CN CN2011101524903A patent/CN102218030A/en active Pending
- 2011-06-10 CN CN2011101541364A patent/CN102247579A/en active Pending
- 2011-06-10 CN CN2011101541294A patent/CN102218037A/en active Pending
- 2011-06-10 CN CN2011101541383A patent/CN102218039A/en active Pending
- 2011-06-10 CN CN2011101541379A patent/CN102218038A/en active Pending
- 2011-07-28 CN CN201310478836.8A patent/CN103919727A/en active Pending
- 2011-07-28 CN CN201310521905.9A patent/CN104323996A/en active Pending
- 2011-07-28 CN CN201310521849.9A patent/CN104323995A/en active Pending
- 2011-07-28 CN CN201310524536.9A patent/CN104324002A/en active Pending
- 2011-07-28 CN CN201310535496.8A patent/CN104337827A/en active Pending
- 2011-07-28 CN CN201310481198.5A patent/CN103816160A/en active Pending
- 2011-07-28 CN CN201310475667.2A patent/CN103919722A/en active Pending
- 2011-07-28 CN CN201310520919.9A patent/CN104323994A/en active Pending
- 2011-07-28 CN CN201310520448.1A patent/CN104337765A/en active Pending
- 2011-07-28 CN CN201310475983.XA patent/CN103919724A/en active Pending
- 2011-07-28 CN CN201310475696.9A patent/CN103919723A/en active Pending
- 2011-07-28 CN CN201310475640.3A patent/CN103919721A/en active Pending
- 2011-07-28 CN CN201310522311.XA patent/CN104323999A/en active Pending
- 2011-07-28 CN CN201310522901.2A patent/CN104324000A/en active Pending
- 2011-07-28 CN CN201310522276.1A patent/CN104323998A/en active Pending
- 2011-07-28 CN CN201310481188.1A patent/CN103768019A/en active Pending
- 2011-07-28 CN CN201310481236.7A patent/CN103768020A/en active Pending
- 2011-07-28 CN CN201310481190.9A patent/CN103919728A/en active Pending
- 2011-07-28 CN CN201310522915.4A patent/CN104323989A/en active Pending
- 2011-07-28 CN CN201310524614.5A patent/CN104324004A/en active Pending
- 2011-07-28 CN CN201310478818.XA patent/CN103919726A/en active Pending
- 2011-07-28 CN CN201310520781.2A patent/CN104323993A/en active Pending
- 2011-07-28 CN CN2011102121399A patent/CN102697726A/en active Pending
- 2011-07-28 CN CN201310520821.3A patent/CN104352438A/en active Pending
- 2011-07-28 CN CN201310524596.0A patent/CN104324003A/en active Pending
- 2011-07-28 CN CN201310524477.5A patent/CN104324001A/en active Pending
- 2011-07-28 CN CN201310481216.XA patent/CN103784402A/en active Pending
- 2011-07-28 CN CN201310475997.1A patent/CN103919725A/en active Pending
- 2011-07-28 CN CN201310522252.6A patent/CN104323997A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4744989A (en) * | 1984-02-08 | 1988-05-17 | E. R. Squibb & Sons, Inc. | Method of preparing liposomes and products produced thereby |
| CN1686123A (en) * | 2005-04-19 | 2005-10-26 | 北京正大绿洲医药科技有限公司 | Pyrolidone hydrochloride drip pill and its preparation method |
| WO2007136129A1 (en) * | 2006-05-23 | 2007-11-29 | Takeda Pharmaceutical Company Limited | Oral preparation comprising pioglitazone |
| WO2008093882A1 (en) * | 2007-02-01 | 2008-08-07 | Takeda Pharmaceutical Company Limited | Solid preparation comprising alogliptin and pioglitazone |
| CN101156853A (en) * | 2007-09-27 | 2008-04-09 | 刘全胜 | Hydrochloric acid glitazone dispersion piece and its preparation method |
| WO2009075391A1 (en) * | 2007-12-13 | 2009-06-18 | Kyushu University, National University Corporation | Drug-containing nanoparticles |
Non-Patent Citations (1)
| Title |
|---|
| 雷国峰等: "流化床包衣法制备灯盏花素前体脂质体的研究", 《中草药》 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104324004A (en) | Pioglitazone liposome combination drug and its large-scale industrial production process | |
| CN103446054A (en) | Liposome combination drugs, industrial production process of liposome combination drug through molecular dispersion method, and quality control | |
| CN101912364B (en) | Ginkgolide B liposome medicinal composition | |
| CN102091035A (en) | Pefloxacin mesilate liposome medicine composition | |
| CN103479579A (en) | Industrialized production of liposome combination medicine by molecular dispersion method, and quality control technology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150204 |